<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2208234020
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vaxneuvance
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        64
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µ/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        270.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD INTERNATIONAL GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD INTERNATIONAL GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Sharp & Dohme B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07AL02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vaxneuvance is a pneumococcal vaccine given to:<br />&bull; children from 6 weeks to less than 18 years of age to help protect against diseases such as lung infection (pneumonia), inflammation of the coverings of the brain and spinal cord (meningitis), a severe infection in the blood (bacteraemia) and ear infections (acute otitis media),<br />&bull; individuals 18 years of age and older to help protect against diseases such as lung infection (pneumonia), inflammation of the coverings of the brain and spinal cord (meningitis) and a severe infection in the blood (bacteraemia), caused by 15 types of bacteria called Streptococcus pneumoniae or pneumococcus.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not receive Vaxneuvance if:<br />&bull; you or your child is allergic to the active substances or to any of the ingredients of this vaccine (listed in section 6), or to any vaccine that contains diphtheria toxoid.<br />Warnings and precautions<br />Talk to your doctor, pharmacist, or nurse before you or your child receives Vaxneuvance if:<br />&bull; the immune system is weak (which means the body is less able to fight off infections) or if you or your child is taking certain medicines that may make the immune system weak (for example, immunosuppressants or steroids).<br />&bull; you or your child has a high fever or severe infection. In these cases, the vaccination may have to be postponed until you or your child has recovered. However, a mild fever or infection (for example having a cold) itself is not a reason to delay vaccination</p><p>&bull; you or your child has any bleeding problems, bruises easily, or is taking medicines to prevent blood clots.<br />If your child is an infant, also tell your doctor if your child was born prematurely (too early).<br />As with any vaccine, Vaxneuvance may not fully protect all persons who are vaccinated.<br />Other medicines/vaccines and Vaxneuvance<br />Your child can be given Vaxneuvance at the same time as other routine childhood vaccines.<br />In adults, Vaxneuvance can be given at the same time as the flu (inactivated influenza) vaccine.<br />Tell your doctor, pharmacist, or nurse if:<br />&bull; you or your child is taking, has recently taken, or might take any prescription medicines (for example, immunosuppressants or steroids which may make the immune system weak) or any medicines obtained without a prescription.<br />&bull; you or your child has recently received or plan to receive any other vaccine.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist, or nurse for advice before you receive this vaccine.<br />Driving and using machines<br />Vaxneuvance has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4 &ldquo;Possible side effects&rdquo; may temporarily affect the ability to drive or use machines.<br />Vaxneuvance contains sodium<br />This medicine contains less than 1 mmol sodium (23 milligrams) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor, pharmacist, or nurse if you or your child has been given a pneumococcal vaccine before.<br />Your doctor or nurse will give the vaccine into your arm muscle or into your child&#39;s arm or leg muscle.<br />Infants and children aged 6 weeks to less than 2 years<br />Your child should receive an initial course of 2 injections of the vaccine followed by a booster dose.<br />&bull; The first injection may be given as early as 6 weeks of age.<br />&bull; A second injection is administered 2 months later.<br />&bull; A third injection (booster) will be given between 11 through 15 months of age.<br />You will be told when your child should come back for each injection.<br />According to official recommendations in your country, an alternative schedule of 3 injections followed by a booster dose may be used by your healthcare provider. Please speak to your doctor, pharmacist, or nurse for more information.<br />Premature infants (born earlier than 37 weeks of pregnancy)<br />Your child should receive an initial course of 3 injections of the vaccine followed by a booster dose.<br />&bull; The first injection may be given as early as 6 weeks of age.<br />&bull; The second and third injections are given thereafter with an interval of 4 to 8 weeks between doses.<br />&bull; A fourth injection (booster) will be given between 11 through 15 months of age.<br />3<br />Infants, children and adolescents starting the vaccination at 7 months of age or older<br />Infants 7 to less than 12 months of age should receive a total of 3 injections. The first two injections will be given at least 1 month apart. The third injection (booster) will be given after 12 months of age and at least 2 months after the second injection.<br />Children 12 months to less than 2 years of age should receive a total of 2 injections. The two injections will be given at least 2 months apart.<br />Children and adolescents 2 to less than 18 years of age should receive 1 injection.<br />Adults<br />Adults should receive 1 injection.<br />Special populations<br />One or more injections of Vaxneuvance may be given to individuals who have one or more underlying conditions that increase their risk for pneumococcal disease (such as individuals with sickle cell disease or living with human immunodeficiency virus [HIV] or recipients of a stem cell transplant).<br />If you have any further questions on the use of Vaxneuvance, ask your doctor, pharmacist, or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all vaccines, Vaxneuvance can cause side effects, although not everybody gets them.<br />Get medical care right away if you or your child has symptoms of an allergic reaction, which may include:<br />&bull; Wheezing or trouble breathing<br />&bull; Swelling of the face, lips, or tongue<br />&bull; Hives<br />&bull; Rash<br />The following side effects can be seen after the use of Vaxneuvance in infants, children and adolescents:<br />Very common (may affect more than 1 in 10 people):<br />&bull; Fever (temperature of 38 &deg;C or higher in those 6 weeks to less than 2 years of age)<br />&bull; Irritability (in those 6 weeks to less than 2 years of age)<br />&bull; Drowsiness (in those 6 weeks to less than 2 years of age)<br />&bull; Pain, redness or swelling at the injection site<br />&bull; Decreased appetite (in those 6 weeks to less than 2 years of age)<br />&bull; Hardness at the injection site (in those 6 weeks to less than 2 years of age)<br />&bull; Muscle aches (in those 2 to less than 18 years of age)<br />&bull; Feeling tired (in those 2 to less than 18 years of age)<br />&bull; Headache (in those 2 to less than 18 years of age)<br />Common (may affect up to 1 in 10 people):<br />&bull; Hardness at the injection site (in those 2 to less than 18 years of age)<br />&bull; Hives<br />&bull; Fever (temperature of 38 &deg;C or higher in those 2 to less than 18 years of age)<br />&bull; Vomiting (in those 6 weeks to less than 2 years of age)<br />&bull; Rash (in those 6 weeks to less than 2 years of age)<br />&bull; Irritability (in those 2 to less than 18 years of age)<br />&bull; Drowsiness (in those 2 to less than 18 years of age)<br />&bull; Decreased appetite (in those 2 to less than 18 years of age)<br />&bull; Bruising at the injection site<br />&bull; Nausea (in those 2 to less than 18 years of age)<br />4<br />Uncommon (may affect up to 1 in 100 people):<br />&bull; Vomiting (in those 2 to less than 18 years of age)<br />Not known (cannot be estimated from the available data):<br />&bull; Rash (in those 2 to less than 18 years of age)<br />The following side effects can be seen after the use of Vaxneuvance in adults:<br />Very common (may affect more than 1 in 10 people):<br />&bull; Pain, swelling, or redness at the injection site<br />&bull; Feeling tired<br />&bull; Muscle aches<br />&bull; Headaches<br />&bull; Joint pain (in those 18 to 49 years of age)<br />Common (may affect up to 1 in 10 people):<br />&bull; Joint pain (in those 50 years of age and older)<br />&bull; Nausea (in those 18 to 49 years of age)<br />&bull; Fever (in those 18 to 49 years of age)<br />&bull; Itchiness at the injection site<br />&bull; Dizziness (in those 18 to 49 years of age)<br />&bull; Chills (in those 18 to 49 years of age)<br />Uncommon (may affect up to 1 in 100 people):<br />&bull; Fever (in those 50 years of age and older)<br />&bull; Warmth at the injection site<br />&bull; Bruising at the injection site<br />&bull; Dizziness (in those 50 years of age and older)<br />&bull; Nausea (in those 50 years of age and older)<br />&bull; Vomiting<br />&bull; Chills (in those 50 years of age and older)<br />&bull; Rash<br />Rare (may affect up to 1 in 1,000 people):<br />&bull; Allergic reaction such as hives, tongue swelling, flushing, and throat tightness<br />These side effects are generally mild and last a short time.<br />Reporting of side effects<br />If you or your child gets any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance Centre (NPC), SFDA.By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this vaccine out of the sight and reach of children.<br />Do not use this vaccine after the expiry date which is stated on the carton and syringe label after EXP. The expiry date refers to the last day of that month.<br />Store in a refrigerator (2 &deg;C &ndash; 8 &deg;C). Do not freeze. Keep the pre-filled syringe in the outer carton in order to protect from light.</p><p>Vaxneuvance should be administered as soon as possible after being removed from the refrigerator. However, in circumstances where Vaxneuvance is temporarily held outside of refrigeration, the vaccine is stable at temperatures up to 25 &deg;C for 48 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are:<br />- bacterial sugars from pneumococcus types 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F (2.0 micrograms of each type);<br />- bacterial sugar from pneumococcus type 6B (4.0 micrograms).<br />Each bacterial sugar is linked to a carrier protein (CRM197). The bacterial sugars and the carrier protein are not alive and do not cause disease.<br />One dose (0.5 mL) contains approximately 30 micrograms carrier protein, adsorbed on aluminium phosphate (125 micrograms aluminium [Al3+]). Aluminium phosphate is included in the vaccine as an adjuvant. Adjuvants are included to improve the immune responses of vaccines.<br />The other ingredients are sodium chloride (NaCl), L-histidine, polysorbate 20, and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vaxneuvance is an opalescent suspension for injection, provided in a single-dose, pre-filled syringe (0.5 mL). Vaxneuvance is available in pack sizes of 1 or 10, either without needles, with 1 separate needle, or with 2 separate needles.
Vaxneuvance is also available in multipacks comprising 5 cartons, each containing 10 pre-filled syringes without needles.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder &amp; Packaging Site:<br />Merck Sharp &amp; Dohme B.V.<br />Waarderweg 39<br />2031 BN Haarlem<br />The Netherlands<br />Manufacturer:<br />MSD International GmbH T/A MSD Ireland (Carlow)<br />Dublin Road,<br />Carlow, Co. Carlow,<br />Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in { Sep 2023}.
To report any side effect(s):
• Saudi Arabia:
The National Pharmacovigilance Centre (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa
• Other GCC States:
Please contact the relevant competent authority.
6
This is a Medicament
− Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
− Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
− The doctor and the pharmacist are the experts in medicines, their benefits and risks.
− Do not by yourself interrupt the period of treatment prescribed for you.
− Do not repeat the same prescription without consulting your doctor.
− Keep all medicaments out of reach of children.
Council of Arab Health Ministers
Union of Arab Pharmacists
This patient information leaflet is approved by the Saudi Food & Drug Authority.
<------------------------------------------------------------------------------------------------------------------------>
The following information is intended for healthcare professionals only:
Vaxneuvance must not be injected intravascularly.
• Immediately prior to use, hold the pre-filled syringe horizontally and shake vigorously to obtain an opalescent suspension. Do not use the vaccine if it cannot be resuspended.
• Inspect the suspension visually for particulate matter and discolouration prior to administration. Discard the vaccine if particulates are present and/or if it appears discoloured.
• Attach a needle with Luer lock connection by twisting in a clockwise direction until the needle fits securely on the syringe.
• Inject immediately using the intramuscular (IM) route, preferably in the anterolateral aspect of the thigh in infants or in the deltoid area of the upper arm in children and adults.
• Exercise care to avoid harm from an accidental needle stick.
No data are available for administration via the intradermal route.
Vaxneuvance must not be mixed with any other vaccines in the same syringe.
Vaxneuvance can be given concomitantly with other routine childhood vaccines.
Vaxneuvance can be administered concomitantly with seasonal quadrivalent influenza vaccine (split virion, inactivated) in adults.
Different injectable vaccines should always be administered at different injection sites.
Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Keep the pre-filled syringe in the outer carton in order to protect from light.
Vaxneuvance should be administered as soon as possible after being removed from the refrigerator.
In the event of temporary temperature excursions, stability data indicate that Vaxneuvance is stable at temperatures up to 25 °C for 48 hours.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">فاكسنيوفانس هو لقاح ضد المكورات الرئوية يُعطى في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>للأطفال من عمر 6 أسابيع إلى أقل من 18 عامًا</strong> للمساعدة في الحماية من الإصابة بأمراض مثل عدوى الرئة (الالتهاب الرئوي)، والتهاب أغشية الدماغ والحبل الشوكي (التهاب السحايا)، والعدوى الشديدة في الدم (تجرثم الدم) والتهابات الأذن (التهاب الأذن الوسطى الحاد)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأفراد الذين تبلغ أعمارهم 18&nbsp;عامًا أو أكثر</strong> للمساعدة في الحماية من الإصابة بالأمراض التي يُسببها 15 نوعًا من البكتيريا التي تُسمى العِقديّة الرئوية أو المكورات الرئوية، مثل عدوى الرئة (الالتهاب الرئوي)، والتهاب أغشية الدماغ والحبل الشوكي (التهاب السحايا) ، والعدوى الشديدة في الدم (تجرثم الدم). &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا ينبغي أن تتلقى فاكسنيوفانس إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك حساسية (رد فعل تحسّسي) نحو المادة الفعّالة أو نحو أي من المكونات المذكورة في القسم رقم 6، أو نحو أي لقاح يحتوي على ذيفان الدفتيريا.</p><p dir="RTL"><strong>التحذيرات &nbsp;والاحتياطات</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة قبل أن تتلقّى أنت أو طفلك فاكسنيوفانس إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من ضعف جهاز المناعة (مما يعني أن قدرة الجسم على مقاومة العدوى أقل من المعتاد) أو إذا كنت أنت أو طفلك تتناول بعض الأدوية التي قد تضعف جهاز المناعة لديك (على سبيل المثال، مثبطات المناعة أو الستيرويدات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أو لدى طفلك حمى شديدة أو عدوى شديدة. في هذه الحالات، قد يتم تأجيل التطعيم حتى تتعافى أنت أو طفلك. ومع ذلك، فإن الحمى أو العدوى الخفيفة (مثل الإصابة بنزلة برد) في حد ذاتها لا يُعد سببًا لتأخير التطعيم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك أو لدى طفلك أي مشاكل نزيف أو سهولة الإصابة بالكدمات أو تتناول أنت أو طفلك أدوية لمنع تجلط الدم.</p><p dir="RTL">إذا كان طفلك رضيعًا، أخبر طبيبك أيضًا إذا ولد طفلك قبل الأوان (خديج).</p><p dir="RTL">كما هو الحال مع أي لقاح، قد لا يُؤمّن فاكسنيوفانس الحماية الكاملة لجميع الأشخاص الذين يتم تطعيمهم.</p><p dir="RTL"><strong>الأدوية /اللقاحات الأخرى وفاكسنيوفانس</strong></p><p dir="RTL">يمكن إعطاء طفلك فاكسنيوفانس في الوقت نفسه الذي يتم فيه إعطاء لقاحات الأطفال الروتينية الأخرى.</p><p dir="RTL">يمكن إعطاء فاكسنيوفانس للكبار في الوقت نفسه مع لقاح الأنفلونزا (فيروس الأنفلونزا المعطل).</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت أنت أو طفلك تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدوية موصوفة (على سبيل المثال، مثبطات المناعة أو الستيرويدات التي قد تضعف جهاز المناعة لديك) أو أي أدوية يمكن الحصول عليها بدون وصفة طبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلقيت أنت أو طفلك مؤخرًا أو تخطط لتلقي أي لقاح آخر.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعةً، تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبك أو الصيدلي أو الممرضة قبل تلقّي هذا اللقاح.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">فاكسنيوفانس ليس له تأثير يُذكر أو له تأثير ضئيل على القدرة على القيادة واستخدام الآلات. ومع ذلك، فإن بعض الآثار المذكورة في القسم 4 &quot;الأعراض الجانبية المحتملة&quot; قد تؤثر مؤقتًا على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>فاكسنيوفانس يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1&nbsp;ملي مول صوديوم (23 مليجرام) لكل جرعة، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُعطى فاكسنيوفانس كحقنة واحدة من قبل طبيبك أو الصيدلي أو الممرضة في عضلة ذراعك أو عضلة ذراع أو ساق طفلك.</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت قد تلقيت أنت أو طفلك لقاح المكورات الرئوية من قبل.</p><p dir="RTL"><strong><u>الرضع والأطفال الذين تتراوح أعمارهم بين 6 ستة أسابيع إلى أقل من سنتين</u></strong></p><p dir="RTL">يجب أن يتلقى طفلك اللقاح على شكل دورة أولية مكونة من حقنتين من اللقاح تليها جرعة معززة.</p><p dir="RTL">&bull; يمكن إعطاء الحقنة الأولى بدءًا من عمر 6 &nbsp;ستة أسابيع.</p><p dir="RTL">&bull; تُعطى الحقنة الثانية بعد شهرين من الجرعة الأولى.</p><p dir="RTL">&bull; ثم تُعطى الحقنة الثالثة (معززة) بين عمر 11 إلى 15 شهرًا.</p><p dir="RTL">سيتم إخبارك متى يجب أن يعود طفلك لتلقي كل جرعة لقاح.</p><p dir="RTL">قد يستخدم مقدم الرعاية الصحية الخاص بك جدولًا بديلاً يتكون من 3 حقن تليها جرعة معززة وذلك وفقًا للتوصيات الرسمية في بلدك. يرجى التحدث إلى طبيبك أو الصيدلي أو الممرضة لمزيد من المعلومات.</p><p dir="RTL"><strong><u>الأطفال الخُدج (المولودون قبل الأسبوع 37 من الحمل)</u></strong></p><p dir="RTL">يجب أن يتلقى طفلك اللقاح على شكل دورة أولية مكونة من 3 &nbsp;ثلاث حُقن من اللقاح تليها جرعة معززة.</p><p dir="RTL">&bull; يمكن إعطاء الحقنة الأولى بدءًا من عمر 6 ستة أسابيع.</p><p dir="RTL">&bull; تُعطى الحقنتين الثانية والثالثة بعد ذلك بفاصل 4 إلى 8 أسابيع بين الجرعات.</p><p dir="RTL">&bull; ثم تُعطى حقنة رابعة (معززة) بين عمر 11 إلى 15 شهرًا.</p><p dir="RTL"><strong><u>الرضع والأطفال والمراهقون ممن يتلقون هذا التطعيم في عمر 7 سبعة أشهر أو أكثر</u></strong></p><p dir="RTL"><strong>يجب أن يتلقى الرضع من عمر 7 إلى أقل من 12 شهرًا</strong> ما مجموعه 3 ثلاث حقن من اللقاح. ينبغي إعطاء الحقنتين الأوليتين بفارق شهر واحد على الأقل بينهما. وتُعطى الحقنة الثالثة (المعززة) بعد عمر 12 شهرًا وبعد شهرين على الأقل من الحقنة الثانية.</p><p dir="RTL"><strong>يجب أن يتلقى الأطفال الذين تتراوح أعمارهم بين 12 شهرًا إلى أقل من عامين</strong> حقنتان اثنتان من اللقاح. تُعطى الحقنتان الاثنتان بفارق شهرين على الأقل بينهما.</p><p dir="RTL"><strong>يجب أن يتلقى الأطفال والمراهقين الذين تتراوح أعمارهم بين عامين وأقل من 18 عامًا</strong> حقنة واحدة من اللقاح.</p><p dir="RTL"><strong><u>البالغون</u></strong></p><p dir="RTL">ينبغي أن يتلقوا حقنة واحدة من اللقاح.</p><p dir="RTL"><strong>الفئات الخاصة من المرضى</strong></p><p dir="RTL">يمكن إعطاء حقنة واحدة أو أكثر من فاكسنيوفانس للأفراد الذين يعانون من حالة مرَضية أو أكثر من الحالات المصاحبة التي تزيد من خطر إصابتهم بمرض المكورات الرئوية (مثل أولئك المصابين بفيروس نقص المناعة البشرية أو ممن خضعوا لزرع خلايا جذعيّة).</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام فاكسنيوفانس، فاسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على غرار جميع اللقاحات، يمكن أن يسبب فاكسنيوفانس أعراضًا جانبية، مع أنها لا تحدث لدى جميع من يتلقاه.</p><p dir="RTL">اطلب الرعاية الطبية على الفور إذا ظهرت لديك أو لدى طفلك أعراض رد فعل تحسسي، والتي قد تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صفير أو صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه أو الشفتين أو اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">يمكن ملاحظة الأعراض الجانبية التالية عند استخدام فاكسنيوفانس لدى الرضّع، والأطفال والمراهقين:</p><p dir="RTL"><strong>شائعة جدًا </strong>(قد تظهر لدى أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (درجة حرارة تبلغ 38 درجة مئوية أو أكثر لدى من تتراوح أعمارهم بين 6 أسابيع إلى أقل من سنتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهيجان (بين من تتراوح أعمارهم بين 6 أسابيع إلى أقل من سنتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النّعاس أو الدوخة (بين من تتراوح أعمارهم بين 6 أسابيع إلى أقل من سنتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;ألم، احمرار أو تورم في مكان الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية (بين من تتراوح أعمارهم بين 6 أسابيع إلى أقل من سنتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبّس في موضع الحقن (بين من تتراوح أعمارهم بين 6 أسابيع إلى أقل من سنتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في العضلات (لدى الأشخاص الذين تتراوح أعمارهم بين عامين وأقل من 18 عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب (لدى الأشخاص الذين تتراوح أعمارهم بين 2 إلى أقل من 18 عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع (لدى الأشخاص الذين تتراوح أعمارهم بين 2 إلى أقل من 18 عامًا)</p><p dir="RTL"><strong>شائعة </strong>(قد تظهر لدى ما يصل إلى 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبّس موضع الحقن (لدى الأشخاص الذين تتراوح أعمارهم بين 2 إلى أقل من 18 عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (درجة حرارة تصل إلى 38 درجة مئوية أو أعلى لدى الأشخاص الذين تتراوح أعمارهم بين عامين وأقل من 18 عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء (لدى الأطفال الذين تتراوح أعمارهم بين ستة أسابيع إلى أقل من عامين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي (لدى الأطفال الذين تتراوح أعمارهم بين ستة أسابيع إلى أقل من عامين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهيجان (لدى الأشخاص الذين تتراوح أعمارهم بين 2 إلى أقل من 18 عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس &nbsp;أو الدوخة (لدى الأشخاص الذين تتراوح أعمارهم بين عامين إلى أقل من 18 عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهيّة (لدى الأشخاص الذين تتراوح أعمارهم بين عامين إلى أقل من 18 عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكدّم موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان (لدى الأشخاص الذين تتراوح أعمارهم بين عامين إلى أقل من 18 عامًا)</p><p dir="RTL"><strong>غير شائعة </strong>(قد تظهر لدى ما يصل إلى 1 من كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء (لدى الأشخاص الذين تتراوح أعمارهم بين عامين إلى أقل من 18 عامًا)</p><p dir="RTL"><strong>ذات التكرار غير المعروف </strong>(لا يمكن تقدير تكرار حدوثها من البيانات المُتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي (لدى الأشخاص الذين تتراوح أعمارهم بين عامين إلى أقل من 18 عامًا)</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن ملاحظة الأعراض الجانبية التالية عند استخدام فاكسنيوفانس لدى البالغين:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تظهر لدى أكثر من شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو تورم أو احمرار في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل (لدى الأشخاص الذين تتراوح أعمارهم بين 18 إلى 49 عامًا)</p><p dir="RTL"><strong>شائعة </strong>(قد تظهر لدى ما يصل إلى 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل (لمن هم في سن الخمسين وما فوق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان (لدى أولئك الذين تتراوح أعمارهم بين 18 و 49 سنة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (لمن تتراوح أعمارهم بين 18 و 49 سنة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة (لدى أولئك الذين تتراوح أعمارهم بين 18 و 49 سنة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة (لمن تتراوح أعمارهم بين 18 و 49 سنة).</p><p dir="RTL"><strong>غير شائعة </strong>(قد تظهر لدى ما يصل إلى 1 من كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (لمن هم في سن الخمسين وما فوق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرارة في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكدّم موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة (لمن هم في سن الخمسين وما فوق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان (لمن هم في سن الخمسين وما فوق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة (لمن هم في سن الخمسين وما فوق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL"><strong>نادرة </strong>(قد تظهر لدى ما يصل إلى 1 من كل 1000 شخص):</p><p dir="RTL">رد فعل تحسسي مثل شرى وتورم اللسان واحمرار الوجه والرقبة وضيق في الحلق</p><p dir="RTL">تُعد الأعراض الجانبية هذه خفيفة بشكل عام وتستمر لفترة قصيرة.</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا شعرت بأي أعراض جانبية، فتحدث مع طبيبك أو الصيدلي أو الممرضة. وهذا يشمل أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عن طريق المركز الوطني للتيقظ والسلامة الدوائية، &nbsp;التابع للهيئة العامة للغذاء والدواء &ndash; المملكة العربية السعودية. يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا اللقاح بعيدًا عن مرأى ومتناول الأطفال .</p><p dir="RTL">لا تستخدم هذا اللقاح بعد تاريخ انتهاء الصلاحية المُدوّن على العلبة ومُلصق المِحقنة بعد كلمة تاريخ انتهاء الصلاحية EXP.</p><p dir="RTL">يُحفظ في الثلاجة في درجة حرارة تتراوح بين (2-8 درجة مئويّة) . لا يُجمد.</p><p dir="RTL">&nbsp;تُحفظ الحقنة في العبوة الأصلية للحماية من الضوء .</p><p dir="RTL">يجب استخدام فاكسنيوفانس في أسرع وقت ممكن بعد إخراجه من الثلاجة. ومع ذلك، إذا حُفظ فاكسنيوفانس مؤقتًا خارج الثلاجة، فإنه يكون مستقرًا عند درجات حرارة تصل إلى 25 درجة مئوية لمدة 48&nbsp;ساعة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات فاكسنيوفانس</strong></p><p dir="RTL"><strong>المواد الفعّالة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكريات البكتيرية من أنواع المكورات الرئوية 1 و 3 و 4 و 5 و 6 A و 7 F و 9 V و 14 و 18&nbsp;C و 19 A و 19 F و 22 F و 23 F و 33 F (2,0&nbsp;ميكروجرام من كل نوع)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكريات البكتيرية من المكورات الرئوية نوع 6 B (4,0 ميكروجرام).</p><p dir="RTL">يرتبط كل سكر بكتيري ببروتين ناقل (CRM<sub>197</sub>). السكريات البكتيرية والبروتينات الناقلة ليست حية ولا تسبب المرض.</p><p dir="RTL">تحتوي الجرعة الواحدة (0,5 مل) على ما يقرب من 30 ميكروجرام من البروتين الناقل، مُمتز على فوسفات الألومنيوم (125 ميكروجرام ألومنيوم [Al<sup>3+</sup>]). يُستخدم فوسفات الألومنيوم في اللقاح كعامل مساعد. استخدام المواد المساعدة في اللقاح يعمل على تحسين الاستجابات المناعية للقاحات.</p><p dir="RTL">المكونات الأخرى هي كلوريد الصوديوم، إل-هيستيدين، بولي سوربات 20، والماء المُخصص للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشكل الصيدلاني لفاكسنيوفانس ووصفه وحجم عبوته</strong></p><p dir="RTL">يتوفر اللقاح على شكل مُعلّق للحقن غير شفاف في مِحقنة مُسبقة التعبئة مُعدة للاستخدام الواحد (0,5&nbsp;مل). وهو متوفر في عُلب تحتوي على عدد 1 حقنة واحدة أو عدد 10 عشر حقن مُسبقة التعبئة إما دون إبر، أو مرفقة مع إبرة واحدة منفصلة أو إبرتين منفصلتين.</p><p dir="RTL">يتوفر فاكسنيوفانس أيضًا في عبوات متعددة المحتوى مكونة من 5 &nbsp;خمس عُلب كرتونية، تحتوي كل منها على عدد &nbsp;10 عشر حقن مملوءة مسبقًا بدون إبر.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات داخل السوق السعودي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق</strong><strong> و</strong><strong>التغليف بواسطة :</strong></p><p dir="RTL">ميرك شارب و دوم بي. في.</p><p dir="RTL">واردرويج 39 هارلم، ٢٠٣١ بي ان</p><p dir="RTL">هولندا</p><p dir="RTL"><strong>الشركة الصانعة:</strong></p><p dir="RTL">إم إس دي إنترناشيونال جي إم بي إتش تي/ إيه أيرلندا (كارلو)</p><p dir="RTL">طريق دبلن</p><p dir="RTL">كارلو، شركة كارلو</p><p dir="RTL">&nbsp;أيرلندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة لهذه النسخة بتاريخ: سبتمبر 2023

للإبلاغ عن أي أعراض جانبية:

·       المملكة العربية السعودية:

-      المركز الوطني للتيقظ والسلامة الدوائية بالمملكة العربية السعودية:

o     مركز الاتصال بالهيئة العامة للغذاء والدواء: 19999

o     البريد الإلكتروني: npc.drug@sfda.gov.sa

o     الموقع الإلكتروني: https://ade.sfda.gov.sa/

·       دول مجلس التعاون الخليجي الأخرى:

يرجى الاتصال بالسلطة المختصة المعنية.

 

هذا دواء

-      الدواء هو منتج يؤثر على صحتك واستهلاكه خلافًا للتعليمات يُعرّضك للخطر.

-      اتبع بدقة وصفة الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي صرف العلاج.

-      الطبيب والصيدلي هما الخبيران في الأدوية وفوائدها ومخاطرها.

-      لا تقطع بنفسك فترة العلاج الموصوفة لك.

-      لا تكرّر نفس الوصفة الطبية بدون استشارة طبيبك.

-      احفظ جميع الأدوية بعيدًا عن متناول الأطفال.

مجلس وزراء الصحة العرب

واتحاد الصيادلة العرب

تمت الموافقة على نشرة معلومات المريض هذه من قبل الهيئة العامة للغذاء والدواء بالمملكة العربية السعودية.

----------------------------------------------------------------

المعلومات التالية مخصصة لاختصاصي الرعاية الصحية فقط:

لا ينبغي حقن فاكسنيوفانس داخل الأوعية الدموية.

·      قبل الاستخدام مباشرة، أمسك المحقنة مسبقة التعبئة بشكل أفقي وقم برجها بقوة للحصول على مُعلّق غير شفاف. لا تستخدم اللقاح إذا تعذّر إعادة تعليق المحلول.

·      افحص المُعلّق بصريًا بحثًا عن أي جسيمات وتغيّر في اللون قبل حقنه. تخلّص من اللقاح إذا كان يحتوي على أي جسيمات و/أو إذا كان لونه متغيرا.

·      قم بتثبيت إبرة بِوَصْلة قفل لور عن طريق لفها في اتجاه عقارب الساعة حتى تثبت الإبرة بإحكام على المحقنة.

·      احقن على الفور باستخدام الحقن العضلي، ويُفضّل أن يكون ذلك في الجانب الأمامي الجانبي من الفخذ عند الرضع أو منطقة العضلة الدّالية في الجزء الأعلى من الذراع عند الأطفال والبالغين.

·      توخّ الحذر لتجنب أي ضرر يُمكن أن ينتج عن الوخز العرضي للإبرة.

لا توجد بيانات متاحة عن الحقن تحت الجلد أو داخل طبقة الأدمة.

يجب عدم خلط فاكسنيوفانس مع أي لقاحات أخرى في المحقنة نفسها.

يمكن إعطاء فاكسنيوفانس بالتزامن مع لقاحات الأطفال الروتينية الأخرى.
يمكن إعطاء فاكسنيوفانس بالتزامن مع لقاح الأنفلونزا الرباعي الموسمي (فيروس مُعطّل ومشطور).
يجب دائمًا حقن اللقاحات المختلفة في مواضع حقن مختلفة.

يحفظ في الثلاجة في درجة حرارة تتراوح بين (2-8 درجة مئوية). لا تجمده.

احفظ المحقنة مسبقة التعبئة داخل العلبة الخارجية لحمايتها من الضوء.

يجب إعطاء فاكسنيوفانس في أسرع وقت ممكن بعد إخراجه من الثلاجة.

في حالة حدوث تغير مؤقت في درجة الحرارة، فإنّ بيانات الاستقرار تشير إلى أنّ فاكسنيوفانس مستقر عند درجات حرارة تصل إلى 25 درجة مئوية لمدة 48 ساعة.

يجب التخلّص من أي منتج طبي أو نفايات غير مستخدمة وفقًا للمتطلبات المحلية.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vaxneuvance suspension for injection in pre filled syringe
Pneumococcal polysaccharide conjugate vaccine (15 valent, adsorbed)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
1 dose (0.5 mL) contains:

Pneumococcal polysaccharide serotype 11,2		2.0 micrograms
Pneumococcal polysaccharide serotype 31,2		2.0 micrograms
Pneumococcal polysaccharide serotype 41,2		2.0 micrograms
Pneumococcal polysaccharide serotype 51,2		2.0 micrograms
Pneumococcal polysaccharide serotype 6A1,2		2.0 micrograms
Pneumococcal polysaccharide serotype 6B1,2		4.0 micrograms
Pneumococcal polysaccharide serotype 7F1,2		2.0 micrograms
Pneumococcal polysaccharide serotype 9V1,2		2.0 micrograms
Pneumococcal polysaccharide serotype 141,2		2.0 micrograms
Pneumococcal polysaccharide serotype 18C1,2		2.0 micrograms
Pneumococcal polysaccharide serotype 19A1,2		2.0 micrograms
Pneumococcal polysaccharide serotype 19F1,2		2.0 micrograms
Pneumococcal polysaccharide serotype 22F1,2		2.0 micrograms
Pneumococcal polysaccharide serotype 23F1,2		2.0 micrograms
Pneumococcal polysaccharide serotype 33F1,2		2.0 micrograms

1Conjugated to CRM197 carrier protein. CRM197 is a nontoxic mutant of diphtheria toxin (originating from Corynebacterium diphtheriae C7) expressed recombinantly in Pseudomonas fluorescens.
2Adsorbed on aluminium phosphate adjuvant.

1 dose (0.5 mL) contains 125 micrograms aluminium (Al3+) and approximately 30 micrograms CRM197 carrier protein.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for injection (injection).
The vaccine is an opalescent suspension.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by <em>Streptococcus pneumoniae</em> in infants, children and adolescents from 6&nbsp;weeks to less than 18&nbsp;years of age.</p><p>&nbsp;</p><p>Vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by <em>Streptococcus pneumoniae</em> in individuals 18&nbsp;years of age and older.</p><p>&nbsp;</p><p>See sections&nbsp;4.4 and 5.1 for information on protection against specific pneumococcal serotypes.</p><p>&nbsp;</p><p>The use of Vaxneuvance should be in accordance with official recommendations.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Routine vaccination schedule in infants and children aged 6&nbsp;weeks to less than 2&nbsp;years </strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Two-dose primary series followed by a booster dose</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>The recommended immunisation regimen consists of 3 doses of Vaxneuvance, each of 0.5&nbsp;mL. The first dose is given as early as 6&nbsp;weeks of age, with a second dose administered 8&nbsp;weeks later. The third (booster) dose is recommended between 11 through 15&nbsp;months of age.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Three-dose primary series followed by a booster dose</em></p><p><strong><em>&nbsp;</em></strong></p></td><td style="vertical-align:top"><p>An immunisation regimen consisting of 4 doses of Vaxneuvance, each of 0.5&nbsp;mL, may be given. This primary series consists of 3&nbsp;doses, with the first dose given as early as 6&nbsp;weeks of age, with an interval of 4 to 8&nbsp;weeks between doses in the primary series. The fourth (booster) dose is recommended between 11 through 15&nbsp;months of age and at least 2&nbsp;months after the third dose.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Preterm infants (&lt;37&nbsp;weeks gestation at birth)</em></p><p><strong><em>&nbsp;</em></strong></p></td><td style="vertical-align:top"><p>The recommended immunisation regimen consists of a three-dose primary series of Vaxneuvance followed by a fourth (booster) dose, each of 0.5&nbsp;mL, as per three-dose primary series followed by a booster dose posology (see sections&nbsp;4.4 and&nbsp;5.1).</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Prior vaccination with another pneumococcal conjugate vaccine</em></p></td><td style="vertical-align:top"><p>Infants and children who have begun immunisation with another pneumococcal conjugate vaccine may switch to Vaxneuvance at any point in the schedule (see section 5.1).</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Catch-up vaccination schedule for children 7 months to less than 18 years of age</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Unvaccinated infants 7 to less than 12 months of age</em></p></td><td style="vertical-align:top"><p>3 doses, each of 0.5 mL, with the first two doses given at least 4&nbsp;weeks apart. A third (booster) dose is recommended after 12&nbsp;months of age, separated from the second dose by at least 2&nbsp;months.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Unvaccinated children 12 months to less than 2 years of age</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>2 doses, each of 0.5 mL, with an interval of 2 months between doses.</p><p><em><u>&nbsp;</u></em></p></td></tr><tr><td style="vertical-align:top"><p><em>Unvaccinated or not fully vaccinated children and adolescents 2 to less than 18 years of age</em></p></td><td style="vertical-align:top"><p>1 dose (0.5 mL).</p><p>&nbsp;</p><p>If a previous pneumococcal conjugate vaccine was administered, at least 2&nbsp;months should elapse before administering Vaxneuvance.</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vaccination schedule for individuals 18 years of age and older</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Individuals 18 years of age and older</em></p></td><td style="vertical-align:top"><p>1 dose (0.5&nbsp;mL).</p><p>&nbsp;</p><p>The need for revaccination with a subsequent dose of Vaxneuvance has not been established.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p>One or more doses of Vaxneuvance may be given to individuals who have one or more underlying conditions predisposing them to an increased risk of pneumococcal disease (such as individuals with sickle cell disease or living with human immunodeficiency virus (HIV) infection or recipients of haematopoietic stem cell transplant (HSCT) or immunocompetent individuals 18 to 49&nbsp;years of age with risk factors for pneumococcal disease; see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>The vaccine should be administered by intramuscular injection. The preferred site is the anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in children and adults.</p><p><u>&nbsp;</u></p><p>No data are available for administration via the intradermal route.</p><p>&nbsp;</p><p>For instructions on the handling of the vaccine before administration, see section&nbsp;6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substances, to any of the excipients listed in section 6.1, or to any diphtheria toxoid containing vaccine.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p><u>&nbsp;</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Precaution related to route of administration</u></p><p><u>&nbsp;</u></p><p>Vaxneuvance must not be administered intravascularly.</p><p>&nbsp;</p><p><u>Anaphylaxis</u></p><p>&nbsp;</p><p>As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.</p><p>&nbsp;</p><p><u>Concurrent illness</u></p><p>&nbsp;</p><p>Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.</p><p>&nbsp;</p><p><u>Thrombocytopenia and coagulation disorders</u></p><p>&nbsp;</p><p>As with other intramuscular injections, the vaccine should be given with caution to individuals receiving anticoagulant therapy, or to those with thrombocytopenia or any coagulation disorder such as haemophilia. Bleeding or bruising may occur following an intramuscular administration in these individuals. Vaxneuvance may be given subcutaneously if the potential benefit clearly outweighs the risks (see section 5.1).</p><p>&nbsp;</p><p><u>Apnoea in premature infants</u></p><p><strong>&nbsp;</strong></p><p>The potential risk of apnoea and the need for respiratory monitoring for 48-72&nbsp;hours should be considered when administering the primary immunisation series to very premature infants (born &le; 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination generally should not be withheld or delayed.</p><p><u>&nbsp;</u></p><p><u>Immunocompromised individuals</u></p><p>&nbsp;</p><p>Immunocompromised individuals, whether due to the use of immuno-suppressive therapy, a genetic defect, HIV infection, or other causes, may have reduced antibody response to active immunisation.</p><p>&nbsp;</p><p>Safety and immunogenicity data for Vaxneuvance are available for individuals with sickle cell disease or living with HIV infection or with a haematopoietic stem cell transplant (see section&nbsp;5.1). Safety and immunogenicity data for Vaxneuvance are not available for individuals in other specific immunocompromised groups and vaccination should be considered on an individual basis.</p><p>&nbsp;</p><p><u>Protection</u></p><p>&nbsp;</p><p>As with any vaccine, vaccination with Vaxneuvance may not protect all vaccine recipients. Vaxneuvance will only protect against <em>Streptococcus pneumoniae</em> serotypes included in the vaccine (see sections&nbsp;2 and 5.1).</p><p>&nbsp;</p><p><u>Sodium</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;milligrams) per dose, i.e. essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Different injectable vaccines should always be administered at different injection sites.</p><p>&nbsp;</p><p>Immunosuppressive therapies may reduce the immune responses to vaccines.</p><p>&nbsp;</p><p><u>Infants and children aged 6&nbsp;weeks to less than 2&nbsp;years</u></p><p>Vaxneuvance can be given concomitantly with any of the following vaccine antigens, either as monovalent or combination vaccines: diphtheria, tetanus, pertussis, poliomyelitis (serotypes 1, 2 and&nbsp;3), hepatitis A, hepatitis B, <em>Haemophilus influenzae </em>type b, measles, mumps, rubella, varicella and rotavirus vaccine.</p><p>&nbsp;</p><p><u>Children and adolescents 2 to less than 18&nbsp;years of age</u></p><p>There are no data on the concomitant administration of Vaxneuvance with other vaccines.</p><p>&nbsp;</p><p>Data from a post-marketing clinical study evaluating the impact of prophylactic use of antipyretics (ibuprofen and paracetamol) on the immune response to other pneumococcal vaccines suggest that administration of antipyretics concomitantly or within the same day of vaccination may reduce the immune response after the infant series. Responses to the booster dose administered at 12 months were unaffected. The clinical significance of this observation is unknown.</p><p>&nbsp;</p><p><u>Adults </u></p><p>Vaxneuvance can be administered concomitantly with seasonal quadrivalent influenza vaccine (split virion, inactivated). There are no data on the concomitant administration of Vaxneuvance with other vaccines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There is limited experience with the use of Vaxneuvance in pregnant women.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Administration of Vaxneuvance in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and the foetus.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>It is unknown whether Vaxneuvance is excreted in human milk.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No human data on the effect of Vaxneuvance on fertility are available. Animal studies in female rats do not indicate harmful effects (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vaxneuvance has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4.8 &ldquo;Undesirable effects&rdquo; may temporarily affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><em>&nbsp;</em></p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p><u>Infants and children aged 6&nbsp;weeks to less than 2&nbsp;years</u></p><p><u>&nbsp;</u></p><p>The safety of Vaxneuvance in healthy infants, including preterm infants (from 6&nbsp;weeks of age at first vaccination) and children (11 through 15&nbsp;months of age) was assessed as a 3 dose or 4 dose regimen in 5 clinical studies with a total of 7,229 participants.</p><p>&nbsp;</p><p>All 5 studies evaluated the safety of Vaxneuvance when administered concomitantly with other routine paediatric vaccines. In these studies, 4,286 participants received a complete regimen of Vaxneuvance, 2,405 participants received a complete regimen of the 13-valent pneumococcal conjugate vaccine (PCV) and 538 participants received Vaxneuvance when used to complete a regimen initiated with the 13-valent PCV (mixed dose regimen).</p><p>&nbsp;</p><p>The most frequent adverse reactions were pyrexia &ge;38&nbsp;&deg;C (75.2%), irritability (74.5%), somnolence (55.0%), injection-site pain (44.4%), injection-site erythema (41.7%), decreased appetite (38.2%), injection-site induration (28.3%) and injection-site swelling (28.2%) based on results in 3,589 participants (Table 1), excluding participants who received a mixed dose regimen. The majority of solicited adverse reactions were mild to moderate (based on intensity or size) and of short duration (&le;3&nbsp;days). Severe reactions (defined as being extremely distressed or unable to do usual activities or size of injection site reaction&nbsp;&gt;7.6&nbsp;cm) occurred in &le;3.5% of infants and children following any dose, with the exception of irritability which occurred in 11.4% of participants.</p><p>&nbsp;</p><p><u>Children and adolescents 2 to less than 18&nbsp;years of age</u></p><p><u>&nbsp;</u></p><p>The safety of Vaxneuvance in healthy children and adolescents was assessed in a study that included 352 participants 2 to less than 18&nbsp;years of age, of whom 177 received a single dose of Vaxneuvance. In this age cohort, 42.9% of all participants had a history of previous vaccination with a lower valency pneumococcal conjugate vaccine.</p><p>&nbsp;</p><p>The most frequent adverse reactions were injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), injection-site induration (6.8%), and pyrexia &ge;38&nbsp;&deg;C (5.6%) (Table 1). The majority of solicited adverse reactions were mild to moderate (based on intensity or size) and of short duration (&le;3&nbsp;days); severe reactions (defined as being extremely distressed or unable to do usual activities or size of injection site reaction&nbsp;&gt;7.6&nbsp;cm) occurred in &le;4.5% of children and adolescents.</p><p>&nbsp;</p><p><u>Adults 18&nbsp;years of age and older</u></p><p><u>&nbsp;</u></p><p>The safety of Vaxneuvance in healthy and immunocompetent adults was assessed in 6&nbsp;clinical studies in 7,136&nbsp;adults &ge;18&nbsp;years of age. An additional clinical study assessed 302&nbsp;adults &ge;18&nbsp;years of age living with HIV. Vaxneuvance was administered to 5,630&nbsp;adults; 1,241&nbsp;were 18 to 49&nbsp;years of age, 1,911&nbsp;were 50 to 64&nbsp;years of age, and 2,478&nbsp;were 65&nbsp;years of age and older. Of those who received Vaxneuvance, 1,134&nbsp;were immunocompetent adults 18 to 49&nbsp;years of age who had no (n=285), 1 (n=620) or &ge;&nbsp;2 (n=229) risk factors for pneumococcal disease and 152&nbsp;were adults &ge;18&nbsp;years of age living with HIV. In addition, 5,253&nbsp;adults were pneumococcal vaccine‑na&iuml;ve and 377&nbsp;adults were previously vaccinated with 23‑valent pneumococcal polysaccharide vaccine (PPV23) at least 1&nbsp;year prior to enrollment.</p><p>&nbsp;</p><p>The most frequently reported adverse reactions following vaccination with Vaxneuvance were solicited. In the pooled analysis of the 7&nbsp;studies, the most frequent adverse reactions were injection-site pain (64.6%), fatigue (23.4%), myalgia (20.7%), headache (17.3%), injection-site swelling (16.1%), injection-site erythema (11.3%) and arthralgia (7.9%) (Table 1). The majority of solicited adverse reactions were mild (based on intensity or size) and of short duration (&le;3&nbsp;days); severe reactions (defined as an event that prevents normal daily activity or size of injection site reaction&nbsp;&gt;10&nbsp;cm) occurred in &le;1.5% of adults across the clinical program.</p><p>&nbsp;</p><p>Older adults reported fewer adverse reactions than younger adults.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><em>&nbsp;</em></p><p>In clinical studies of adults, local and systemic adverse reactions were solicited daily after vaccination for 5 and 14&nbsp;days, respectively and in infants, children and adolescents up to 14 days after vaccination. In all populations, unsolicited adverse reactions were reported for 14&nbsp;days after vaccination.</p><p>&nbsp;</p><p>Adverse reactions reported for all age groups are listed in this section per system organ class, in decreasing order of frequency and seriousness. The frequency is defined as follows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common (&ge;1/10)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common (&ge;1/100 to &lt;1/10)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare (&lt;1/10,000)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table 1: Tabulated list of adverse reactions</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><thead><tr><td rowspan="3" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td rowspan="3" style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infants/Children/Adolescents</strong></p></td><td style="vertical-align:top"><p><strong>Adults</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>6W to &lt;2Y</strong></p></td><td style="vertical-align:top"><p><strong>2 to &lt;18Y<sup>&sect;</sup></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Irritability</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity reaction including tongue oedema, flushing, and throat tightness</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon<sup>&dagger;</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Not known <sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common*</p></td></tr><tr><td rowspan="13" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Pyrexia<sup>⸸</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;39&deg;C</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;40 &deg;C</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Injection‑site pain</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Injection-site erythema</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Injection-site swelling</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Injection-site induration</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Injection-site urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Injection‑site pruritus</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Injection-site warmth</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Injection-site bruising/haematoma</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Chills&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon<sup>&dagger;</sup></p></td></tr></tbody></table><p><sup>&sect;</sup>Different systemic adverse events were solicited for participants 2 to &lt;3&nbsp;years of age, than for participants &ge;3 to less than 18 years of age. For participants &lt;3 years of age (Vaxneuvance N=32, 13-valent PCV N=28), decreased appetite, irritability, somnolence and urticaria were solicited from Day 1 through Day 14 following vaccination. For participants &ge;3 to less than 18 years of age, fatigue, headache, myalgia, and urticaria were solicited from Day 1 through Day 14 following vaccination.</p><p><sup>&dagger;</sup>common in adults 18 to 49&nbsp;years of age</p><p><sup>&Dagger;</sup>In clinical trials, no events were observed following Vaxneuvance in healthy children and adolescents and two events were observed in special populations (sickle cell disease and HIV).</p><p>*very common in adults 18 to 49&nbsp;years of age</p><p><sup>⸸</sup>defined as temperature &ge;38 &deg;C</p><p>&nbsp;</p><p><u>Additional information for other dosing regimens, vaccination schedules and special populations </u></p><p><em>&nbsp;</em></p><p><em>Mixed dose regimen</em> <em>of different pneumococcal conjugate vaccines</em><em> </em></p><p>The safety profiles of mixed 4-dose regimens of Vaxneuvance and the 13-valent PCV in healthy infants and children were generally comparable to those of complete 4-dose regimens of either Vaxneuvance or the 13-valent PCV (see section 5.1).</p><p><u>&nbsp;</u></p><p><em>Catch-up vaccination schedule</em></p><p>Safety was also assessed as a catch-up vaccination schedule in 126 healthy infants and children from 7&nbsp;months to less than 2&nbsp;years of age who received 2 or 3 doses of Vaxneuvance based on age at enrollment. The safety profile of the catch-up vaccination schedule was generally consistent with the safety profile of the routine vaccination schedule initiated from 6 weeks of age (see section 5.1).</p><p><u>&nbsp;</u></p><p><em>Children and adolescents</em><em> </em><em>with sickle cell disease or</em><em> living with HIV</em></p><p>Safety was also assessed in 69 children and adolescents 5 to less than 18 years of age with sickle cell disease and in 203 children and adolescents 6 to less than 18&nbsp;years of age living with HIV, all of whom received a single dose of Vaxneuvance. The safety profile of Vaxneuvance in children with these conditions was generally consistent with the safety profile in healthy children (see section 5.1).</p><p>&nbsp;</p><p><em>Children and adults receiving Haematopoietic Stem Cell Transplant</em></p><p>Safety was also assessed in 131&nbsp;adults and 8&nbsp;children &ge;3 years of age who had received an allogeneic haematopoietic stem cell transplant (allo-HSCT) 3 to 6 months prior to enrollment, all of whom received between 1&nbsp;and&nbsp;4 doses of Vaxneuvance. The safety profile of Vaxneuvance in recipients of allo-HSCT was generally consistent with the safety profile in a healthy population.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data with regard to overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group: vaccines, pneumococcal vaccines, ATC code: J07AL02</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Vaxneuvance contains 15 purified pneumococcal capsular polysaccharides from <em>Streptococcus pneumoniae</em> (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, with the additional serotypes 22F and 33F), each conjugated to a carrier protein (CRM<sub>197</sub>). Vaxneuvance elicits a T‑cell dependent immune response to induce antibodies that enhance opsonisation, phagocytosis, and killing of pneumococci to protect against pneumococcal disease.</p><p>&nbsp;</p><p>Immune responses following natural exposure to <em>Streptococcus pneumoniae</em> or following pneumococcal vaccination can be determined by measuring opsonophagocytic activity (OPA) and immunoglobulin G (IgG) responses. OPA represents functional antibodies and is considered an important immunologic surrogate measure of protection against pneumococcal disease in adults. In children, a serotype-specific IgG antibody level corresponding to &ge;0.35&nbsp;&micro;g/mL using the WHO enzyme linked immunosorbent assay (ELISA) has been used as the threshold value for the clinical evaluation of pneumococcal conjugate vaccines.</p><p>&nbsp;</p><p><u>Clinical immunogenicity in healthy infants, children and adolescents</u></p><p><em><u>&nbsp;</u></em></p><p>Immunogenicity was assessed by serotype‑specific IgG response rates (the proportion of participants meeting the serotype‑specific IgG threshold value of &ge;0.35&nbsp;&micro;g/mL) and IgG geometric mean concentrations (GMCs) at 30 days following the primary series and/or following the toddler (booster) dose. In a subset of participants, OPA geometric mean titres (GMTs) were also measured at 30 days following the primary series and/or following the toddler dose.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Infants and children receiving a routine vaccination schedule</u></em></p><p><em>&nbsp;</em></p><p><em>3-dose regimen (2-dose primary series + 1 toddler dose)</em></p><p>In the double-blind, active comparator-controlled study (Protocol&nbsp;025), 1,184 participants were randomised to receive Vaxneuvance or the 13-valent PCV in a 3-dose regimen. The first two doses were administered to infants at 2 and 4&nbsp;months of age (primary series) and the third dose was administered to children at 11 through 15&nbsp;months of age (toddler dose). Participants also received other paediatric vaccines concomitantly, including Rotavirus vaccine (live) with the infant primary series and Diphtheria, Tetanus, Pertussis (acellular), Hepatitis B (rDNA), Poliomyelitis (inactivated), <em>Haemophilus influenzae </em>type b conjugate vaccine (adsorbed) with all 3 doses in the complete regimen.</p><p>&nbsp;</p><p>Vaxneuvance elicits immune responses, as assessed by IgG response rates, IgG GMCs and OPA GMTs, for all 15 serotypes contained in the vaccine. At 30 days following the two-dose primary series, serotype-specific IgG response rates and GMCs were generally comparable for the 13&nbsp;shared serotypes and higher for the 2&nbsp;additional serotypes (22F and 33F) in Vaxneuvance recipients, compared to the 13-valent PCV recipients (Table 2). At 30 days following the toddler dose, Vaxneuvance is noninferior to the 13-valent PCV for the 13&nbsp;shared serotypes and superior for the 2&nbsp;additional serotypes, as assessed by IgG response rate and IgG GMCs (Table 3).</p><p><strong>&nbsp;</strong></p><p><strong>Table 2: Serotype-specific IgG response rates and IgG GMCs at 30 days following the 2-dose primary series (3-dose regimen, Protocol&nbsp;025)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3"><p><strong>Pneumococcal Serotype</strong></p></td><td colspan="3"><p><strong>IgG response rates &ge;0.35&nbsp;&micro;g/mL</strong></p></td><td colspan="3"><p><strong>IgG GMCs</strong></p></td></tr><tr><td><p><strong>Vaxneuvance</strong></p><p><strong>(n=497)</strong></p></td><td><p><strong>13-valent PCV (n=468-469)</strong></p></td><td rowspan="2"><p><strong>Percentage Point Difference*</strong></p><p><strong>(Vaxneuvance - 13-valent PCV)</strong></p><p><strong>(95% CI)*</strong></p></td><td><p><strong>Vaxneuvance</strong></p><p><strong>(n=497)</strong></p></td><td><p><strong>13-valent PCV (n=468-469)</strong></p></td><td rowspan="2"><p><strong>GMC Ratio**</strong></p><p><strong>(Vaxneuvance/</strong></p><p><strong>13-valent PCV)</strong></p><p><strong>(95%&nbsp;CI)**</strong></p></td></tr><tr><td><p><strong>Observed Response</strong></p><p><strong>Percentage</strong></p></td><td><p><strong>Observed Response</strong></p><p><strong>Percentage</strong></p></td><td><p><strong>GMC</strong></p></td><td><p><strong>GMC</strong></p></td></tr><tr><td colspan="7"><p>13&nbsp;Shared Serotypes<sup>&dagger;</sup></p></td></tr><tr><td><p>1</p></td><td style="vertical-align:top"><p>95.6</p></td><td style="vertical-align:top"><p>97.4</p></td><td style="vertical-align:top"><p>-1.9 (-4.3, 0.5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.81 (0.74, 0.89)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>3</p></td><td style="vertical-align:top"><p>93.2</p></td><td style="vertical-align:top"><p>66.1</p></td><td style="vertical-align:top"><p>27.1 (22.3, 31.9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.91 (1.75, 2.08)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>4</p></td><td style="vertical-align:top"><p>93.8</p></td><td style="vertical-align:top"><p>96.8</p></td><td style="vertical-align:top"><p>-3.0 (-5.9, -0.4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.12 (1.01, 1.24)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>5</p></td><td style="vertical-align:top"><p>84.1</p></td><td style="vertical-align:top"><p>88.1</p></td><td style="vertical-align:top"><p>-4.0 (-8.3, 0.4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.86 (0.76, 0.97)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>6A</p></td><td style="vertical-align:top"><p>72.6</p></td><td style="vertical-align:top"><p>92.3</p></td><td style="vertical-align:top"><p>-19.7 (-24.3, -15.1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.46 (0.40, 0.53)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>6B</p></td><td style="vertical-align:top"><p>57.7</p></td><td style="vertical-align:top"><p>50.2</p></td><td style="vertical-align:top"><p>7.5 (1.2, 13.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.31 (1.11, 1.56)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>7F</p></td><td style="vertical-align:top"><p>97.8</p></td><td style="vertical-align:top"><p>98.9</p></td><td style="vertical-align:top"><p>-1.1 (-3.0, 0.5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.84 (0.76, 0.92)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>9V</p></td><td style="vertical-align:top"><p>88.3</p></td><td style="vertical-align:top"><p>95.3</p></td><td style="vertical-align:top"><p>-7.0 (-10.5, -3.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.88 (0.78, 0.99)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>14</p></td><td style="vertical-align:top"><p>96.8</p></td><td style="vertical-align:top"><p>97.2</p></td><td style="vertical-align:top"><p>-0.4 (-2.7, 1.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3.81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>4.88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.78 (0.68, 0.90)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>18C</p></td><td style="vertical-align:top"><p>92.2</p></td><td style="vertical-align:top"><p>92.5</p></td><td style="vertical-align:top"><p>-0.4 (-3.8, 3.0)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.89 (0.80, 0.99)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>19A</p></td><td style="vertical-align:top"><p>96.2</p></td><td style="vertical-align:top"><p>97.2</p></td><td style="vertical-align:top"><p>-1.1 (-3.4, 1.3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.81 (0.72, 0.90)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>19F</p></td><td style="vertical-align:top"><p>98.8</p></td><td style="vertical-align:top"><p>99.4</p></td><td style="vertical-align:top"><p>-0.6 (-2.0, 0.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.79 (0.71, 0.87)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>23F</p></td><td style="vertical-align:top"><p>77.9</p></td><td style="vertical-align:top"><p>70.1</p></td><td style="vertical-align:top"><p>7.8 (2.3, 13.3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.30 (1.14, 1.50)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td colspan="7"><p>2&nbsp;Additional Serotypes in Vaxneuvance<sup>&Dagger;</sup></p></td></tr><tr><td><p>22F</p></td><td style="vertical-align:top"><p>95.6</p></td><td style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>90.2 (87.1, 92.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>57.67 (50.95, 65.28)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>33F</p></td><td style="vertical-align:top"><p>48.1</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>45.1 (40.4, 49.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>6.11 (5.32, 7.02)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>* Estimated difference and CI for the percentage point difference are based on the Miettinen &amp; Nurminen method.</p><p>** GMC ratio and CI are calculated using the t-distribution with the variance estimate from a serotype-specific linear model utilising the natural log-transformed antibody concentrations as the response and a single term for vaccination group.</p><p><sup>&dagger;</sup> A conclusion of non-inferiority for the 13&nbsp;shared serotypes is based on the lower bound of the 95%&nbsp;CI being &gt; -10&nbsp;percentage points for the difference in IgG response rates (Vaxneuvance &ndash; 13-valent PCV) or &gt; 0.5 for the IgG GMC ratio (Vaxneuvance/13-valent PCV).</p><p><sup>&Dagger;</sup> A conclusion of superiority for the 2 additional&nbsp;serotypes is based on the lower bound of the 95%&nbsp;CI being &gt; 10&nbsp;percentage points for the difference in IgG response rates (Vaxneuvance &ndash; 13-valent PCV) or &gt; 2.0 for the IgG GMC ratio (Vaxneuvance/13-valent PCV).</p><p>n=Number of participants randomised, vaccinated and contributing to the analysis.</p><p>CI=confidence interval; GMC=geometric mean concentration (&micro;g/mL); IgG=immunoglobulin G.</p><p>&nbsp;</p><p><strong>Table 3: Serotype-specific IgG response rates and IgG GMCs at 30 days following the toddler dose (3-dose regimen, Protocol&nbsp;025)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3"><p><strong>Pneumococcal Serotype</strong></p></td><td colspan="3"><p><strong>IgG response rates &ge;0.35&nbsp;&micro;g/mL</strong></p></td><td colspan="3"><p><strong>IgG GMCs</strong></p></td></tr><tr><td><p><strong>Vaxneuvance</strong></p><p><strong>(n=510-511)</strong></p></td><td><p><strong>13-valent PCV (n=504-510)</strong></p></td><td rowspan="2"><p><strong>Percentage Point Difference*</strong></p><p><strong>(Vaxneuvance - 13-valent PCV)</strong></p><p><strong>(95% CI)*</strong></p></td><td><p><strong>Vaxneuvance</strong></p><p><strong>(n=510-511)</strong></p></td><td><p><strong>13-valent PCV (n=504-510)</strong></p></td><td rowspan="2"><p><strong>GMC Ratio**</strong></p><p><strong>(Vaxneuvance/</strong></p><p><strong>13-valent PCV)</strong></p><p><strong>(95%&nbsp;CI)**</strong></p></td></tr><tr><td><p><strong>Observed Response</strong></p><p><strong>Percentage</strong></p></td><td><p><strong>Observed Response</strong></p><p><strong>Percentage</strong></p></td><td><p><strong>GMC</strong></p></td><td><p><strong>GMC</strong></p></td></tr><tr><td colspan="7"><p>13&nbsp;Shared Serotypes<sup>&dagger;</sup></p></td></tr><tr><td><p>1</p></td><td><p>96.5</p></td><td><p>99.4</p></td><td><p>-2.9 (-5.0, -1.3)</p></td><td style="vertical-align:top"><p>1.28</p></td><td style="vertical-align:top"><p>2.05</p></td><td style="vertical-align:top"><p>0.62 (0.57, 0.68)</p></td></tr><tr><td><p>3</p></td><td><p>91.8</p></td><td><p>83.7</p></td><td><p>8.1 (4.1, 12.1)</p></td><td style="vertical-align:top"><p>0.84</p></td><td style="vertical-align:top"><p>0.66</p></td><td style="vertical-align:top"><p>1.29 (1.18, 1.41)</p></td></tr><tr><td><p>4</p></td><td><p>95.7</p></td><td><p>97.8</p></td><td><p>-2.1 (-4.5, 0.0)</p></td><td style="vertical-align:top"><p>1.29</p></td><td style="vertical-align:top"><p>1.74</p></td><td style="vertical-align:top"><p>0.74 (0.67, 0.82)</p></td></tr><tr><td><p>5</p></td><td><p>99.0</p></td><td><p>100.0</p></td><td><p>-1.0 (-2.3, -0.2)</p></td><td style="vertical-align:top"><p>1.98</p></td><td style="vertical-align:top"><p>3.01</p></td><td style="vertical-align:top"><p>0.66 (0.60, 0.72)</p></td></tr><tr><td><p>6A</p></td><td><p>98.4</p></td><td><p>98.8</p></td><td><p>-0.4 (-2.0, 1.2)</p></td><td style="vertical-align:top"><p>3.09</p></td><td style="vertical-align:top"><p>4.53</p></td><td style="vertical-align:top"><p>0.68 (0.61, 0.76)</p></td></tr><tr><td><p>6B</p></td><td><p>97.3</p></td><td><p>99.0</p></td><td><p>-1.8 (-3.7, -0.1)</p></td><td style="vertical-align:top"><p>4.15</p></td><td style="vertical-align:top"><p>4.33</p></td><td style="vertical-align:top"><p>0.96 (0.85, 1.08)</p></td></tr><tr><td><p>7F</p></td><td><p>99.8</p></td><td><p>99.8</p></td><td><p>0.0 (-0.9, 0.9)</p></td><td style="vertical-align:top"><p>3.08</p></td><td style="vertical-align:top"><p>3.89</p></td><td style="vertical-align:top"><p>0.79 (0.73, 0.86)</p></td></tr><tr><td><p>9V</p></td><td><p>98.8</p></td><td><p>100.0</p></td><td><p>-1.2 (-2.5, -0.4)</p></td><td style="vertical-align:top"><p>2.14</p></td><td style="vertical-align:top"><p>2.97</p></td><td style="vertical-align:top"><p>0.72 (0.66, 0.78)</p></td></tr><tr><td><p>14</p></td><td><p>99.8</p></td><td><p>100.0</p></td><td><p>-0.2 (-1.1, 0.6)</p></td><td style="vertical-align:top"><p>5.22</p></td><td style="vertical-align:top"><p>6.90</p></td><td style="vertical-align:top"><p>0.76 (0.68, 0.84)</p></td></tr><tr><td><p>18C</p></td><td><p>98.8</p></td><td><p>99.2</p></td><td><p>-0.4 (-1.8, 1.0)</p></td><td style="vertical-align:top"><p>1.93</p></td><td style="vertical-align:top"><p>2.18</p></td><td style="vertical-align:top"><p>0.89 (0.81, 0.97)</p></td></tr><tr><td><p>19A</p></td><td><p>99.0</p></td><td><p>100.0</p></td><td><p>-1.0 (-2.3, -0.2)</p></td><td style="vertical-align:top"><p>4.65</p></td><td style="vertical-align:top"><p>5.61</p></td><td style="vertical-align:top"><p>0.83 (0.75, 0.92)</p></td></tr><tr><td><p>19F</p></td><td><p>99.6</p></td><td><p>100.0</p></td><td><p>-0.4 (-1.4, 0.4)</p></td><td style="vertical-align:top"><p>4.06</p></td><td style="vertical-align:top"><p>4.59</p></td><td style="vertical-align:top"><p>0.89 (0.81, 0.97)</p></td></tr><tr><td><p>23F</p></td><td><p>96.9</p></td><td><p>97.2</p></td><td><p>-0.4 (-2.6, 1.8)</p></td><td style="vertical-align:top"><p>1.52</p></td><td style="vertical-align:top"><p>1.69</p></td><td style="vertical-align:top"><p>0.90 (0.81, 1.00)</p></td></tr><tr><td colspan="7"><p>2&nbsp;Additional Serotypes in Vaxneuvance<sup>&Dagger;</sup></p></td></tr><tr><td><p>22F</p></td><td><p>99.6</p></td><td><p>5.9</p></td><td><p>93.7 (91.2, 95.5)</p></td><td style="vertical-align:top"><p>5.97</p></td><td style="vertical-align:top"><p>0.08</p></td><td style="vertical-align:top"><p>71.76 (64.88, 79.38)</p></td></tr><tr><td><p>33F</p></td><td><p>99.0</p></td><td><p>4.4</p></td><td><p>94.7 (92.3, 96.3)</p></td><td style="vertical-align:top"><p>3.38</p></td><td style="vertical-align:top"><p>0.07</p></td><td style="vertical-align:top"><p>46.38 (41.85, 51.40)</p></td></tr></tbody></table><p>&nbsp;</p><p>* Estimated difference and CI for the percentage point difference are based on the Miettinen &amp; Nurminen method.</p><p>** GMC ratio and CI are calculated using the t-distribution with the variance estimate from a serotype-specific linear model utilising the natural log-transformed antibody concentrations as the response and a single term for vaccination group.</p><p><sup>&dagger;</sup> A conclusion of non-inferiority for the 13&nbsp;shared serotypes is based on the lower bound of the 95%&nbsp;CI being &gt; -10&nbsp;percentage points for the difference in IgG response rates (Vaxneuvance &ndash; 13-valent PCV) or &gt; 0.5 for the IgG GMC ratio (Vaxneuvance/13-valent PCV).</p><p><sup>&Dagger;</sup> A conclusion of superiority for the 2 additional&nbsp;serotypes is based on the lower bound of the 95%&nbsp;CI being &gt; 10&nbsp;percentage points for the difference in IgG response rates (Vaxneuvance &ndash; 13-valent PCV) or &gt; 2.0 for the IgG GMC ratio (Vaxneuvance/13-valent PCV).</p><p>n=Number of participants randomised, vaccinated and contributing to the analysis.</p><p>CI=confidence interval; GMC=geometric mean concentration (&micro;g/mL); IgG=immunoglobulin G.</p><p>&nbsp;</p><p>Additionally, Vaxneuvance elicits functional antibodies, as assessed by serotype-specific OPA GMTs at 30 days following the toddler dose, that are generally comparable but slightly lower for the 13&nbsp; serotypes shared with 13-valent PCV. The clinical relevance of this slightly lower response is unknown. OPA GMTs for both 22F and 33F were higher in Vaxneuvance recipients compared to the 13-valent PCV recipients.</p><p>&nbsp;</p><p>In another double‑blind, active comparator‑controlled study (Protocol&nbsp;026), 1,191&nbsp;participants were randomised to receive Vaxneuvance or the 13-valent PCV as a 3‑dose regimen given concomitantly with other paediatric vaccines including Vaxelis with all three doses and M-M-RvaxPro and Varivax with the toddler dose. The primary series was administered to infants at 3&nbsp;and 5&nbsp;months of age followed by the toddler dose at 12&nbsp;months of age.</p><p><s>&nbsp;</s></p><p>Vaxneuvance elicits immune responses, as assessed by IgG response rates, IgG GMCs and OPA GMTs, for all 15&nbsp;serotypes contained in the vaccine. At 30&nbsp;days following the toddler dose, Vaxneuvance is non‑inferior to the 13-valent PCV for the 13&nbsp;shared serotypes and superior for the 2&nbsp;additional serotypes, 22F and 33F, as assessed by IgG response rates. Similarly, Vaxneuvance is non-inferior to the 13-valent PCV for the 13&nbsp;shared serotypes and superior to the 13-valent PCV for the 2&nbsp;additional serotypes, as assessed by IgG GMCs. Following the toddler dose, Vaxneuvance generates functional antibodies (OPA GMTs) for all 15 serotypes that are generally comparable with the 13-valent PCV.</p><p>&nbsp;</p><p><em>4-dose regimen (3-dose primary series + 1 toddler dose)</em></p><p>A 4-dose regimen was evaluated in healthy infants in one phase 2 and three phase 3 studies. The primary series were administered to infants at 2, 4, and 6 months of age and the toddler dose was administered to children at 12 through 15 months of age.</p><p>&nbsp;</p><p>In a double‑blind, active comparator‑controlled study (Protocol&nbsp;029), 1,720&nbsp;participants were randomised to receive Vaxneuvance or the 13-valent PCV. Participants also received other paediatric vaccines concomitantly, including HBVaxPro (Hepatitis B Vaccine [Recombinant]), RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent) and Diphtheria, Tetanus Toxoids, Acellular Pertussis Adsorbed, Poliomyelitis (inactivated), <em>Haemophilus</em> b Conjugate (Tetanus Toxoid Conjugate) Vaccine in the infant series. <em>Haemophilus</em> b Conjugate Vaccine (Tetanus Toxoid Conjugate), M‑M‑RvaxPro (Measles, Mumps, and Rubella Virus Vaccine Live), Varivax (Varicella Virus Vaccine Live) and Vaqta (Hepatitis A Vaccine, Inactivated) were administered concomitantly with the toddler dose of Vaxneuvance.</p><p>&nbsp;</p><p>Vaxneuvance elicits immune responses, as assessed by IgG response rates, IgG GMCs and OPA GMTs for all 15&nbsp;serotypes contained in the vaccine. At 30&nbsp;days following the primary series, Vaxneuvance is noninferior to the 13-valent PCV for the 13&nbsp;shared serotypes, as assessed by IgG response rates (Table&nbsp;4). Vaxneuvance is noninferior for the 2&nbsp;additional serotypes, as assessed by the IgG response rates for serotypes 22F and 33F in recipients of Vaxneuvance compared with the response rate for serotype 23F in recipients of the 13-valent PCV (the lowest response rate for any of the shared serotypes, excluding serotype&nbsp;3), with percentage point differences of 6.7% (95%&nbsp;CI: 4.6, 9.2) and ‑4.5% (95%&nbsp;CI: ‑7.8, ‑1.3), respectively.</p><p>&nbsp;</p><p>At 30&nbsp;days following the primary series, serotype‑specific IgG GMCs are noninferior to the 13-valent PCV for 12&nbsp;of the 13&nbsp;shared serotypes. The IgG response to serotype 6A narrowly missed the prespecified noninferiority criteria by a small margin (0.48 versus &gt;0.5) (Table 4). Vaxneuvance is noninferior to the 13-valent PCV for the 2&nbsp;additional serotypes, as assessed by serotype‑specific IgG GMCs for serotypes 22F and 33F in recipients of Vaxneuvance compared with the IgG GMCs for serotype 4 in recipients of the 13-valent PCV (the lowest IgG GMC for any of the shared serotypes, excluding serotype 3) with a GMC ratio of 3.64 and 1.24, respectively.</p><p>&nbsp;</p><p>Additionally, Vaxneuvance induces immune responses to shared serotype 3 and the 2 additional serotypes, which were substantially higher compared to the immune response induced by the 13-valent PCV as assessed by IgG response rates and IgG GMCs at 30&nbsp;days following the primary series (Table&nbsp;4).</p><p>&nbsp;</p><p><strong>Table 4: Serotype-specific IgG response rates and IgG GMCs at 30 days following the 3-dose primary series (4-dose regimen, Protocol&nbsp;029)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3"><p><strong>Pneumococcal Serotype</strong></p></td><td colspan="3"><p><strong>IgG response rates &ge;0.35&nbsp;&micro;g/mL</strong></p></td><td colspan="3"><p><strong>IgG GMCs</strong></p></td></tr><tr><td><p><strong>Vaxneuvance</strong></p><p><strong>(n=698-702)</strong></p></td><td><p><strong>13-valent PCV (n=660-665)</strong></p></td><td rowspan="2"><p><strong>Percentage Point Difference*</strong></p><p><strong>(Vaxneuvance - 13-valent PCV)</strong></p><p><strong>(95% CI)*</strong></p></td><td><p><strong>Vaxneuvance</strong></p><p><strong>(n=698-702)</strong></p></td><td><p><strong>13-valent PCV </strong></p><p><strong>(n=660-665)</strong></p></td><td rowspan="2"><p><strong>GMC Ratio**</strong></p><p><strong>(Vaxneuvance/</strong></p><p><strong>13-valent PCV)</strong></p><p><strong>(95%&nbsp;CI)**</strong></p></td></tr><tr><td><p><strong>Observed Response</strong></p><p><strong>Percentage</strong></p></td><td><p><strong>Observed Response</strong></p><p><strong>Percentage</strong></p></td><td><p><strong>GMC</strong></p></td><td><p><strong>GMC</strong></p></td></tr><tr><td colspan="7"><p>13&nbsp;Shared Serotypes<strong><sup>&dagger;</sup></strong></p></td></tr><tr><td><p>1</p></td><td style="vertical-align:top"><p>95.7</p></td><td style="vertical-align:top"><p>99.1</p></td><td style="vertical-align:top"><p>-3.4 (-5.2, -1.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.64 (0.59, 0.69)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>3</p></td><td style="vertical-align:top"><p>94.7</p></td><td style="vertical-align:top"><p>79.2</p></td><td style="vertical-align:top"><p>15.6 (12.1, 19.2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.73 (1.61, 1.87)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>4</p></td><td style="vertical-align:top"><p>96.4</p></td><td style="vertical-align:top"><p>98.6</p></td><td style="vertical-align:top"><p>-2.2 (-4.0, -0.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.95 (0.88, 1.03)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>5</p></td><td style="vertical-align:top"><p>95.3</p></td><td style="vertical-align:top"><p>97.4</p></td><td style="vertical-align:top"><p>-2.1 (-4.2, -0.2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.72 (0.66, 0.80)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>6A</p></td><td style="vertical-align:top"><p>93.7</p></td><td style="vertical-align:top"><p>98.6</p></td><td style="vertical-align:top"><p>-4.9 (-7.1, -3.0)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.52 (0.48, 0.58)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>6B</p></td><td style="vertical-align:top"><p>88.6</p></td><td style="vertical-align:top"><p>92.0</p></td><td style="vertical-align:top"><p>-3.4 (-6.6, -0.3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.81 (0.71, 0.93)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>7F</p></td><td style="vertical-align:top"><p>99.0</p></td><td style="vertical-align:top"><p>99.8</p></td><td style="vertical-align:top"><p>-0.8 (-1.9, -0.1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.77 (0.71, 0.83)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>9V</p></td><td style="vertical-align:top"><p>97.1</p></td><td style="vertical-align:top"><p>98.2</p></td><td style="vertical-align:top"><p>-1.0 (-2.8, 0.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.91 (0.84, 1.00)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>14</p></td><td style="vertical-align:top"><p>97.9</p></td><td style="vertical-align:top"><p>97.9</p></td><td style="vertical-align:top"><p>-0.0 (-1.6, 1.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>4.78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>6.80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.70 (0.63, 0.78)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>18C</p></td><td style="vertical-align:top"><p>97.4</p></td><td style="vertical-align:top"><p>98.3</p></td><td style="vertical-align:top"><p>-0.9 (-2.6, 0.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.00&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.76 (0.70, 0.83)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>19A</p></td><td style="vertical-align:top"><p>97.9</p></td><td style="vertical-align:top"><p>99.7</p></td><td style="vertical-align:top"><p>-1.8 (-3.2, -0.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.71 (0.65, 0.77)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>19F</p></td><td style="vertical-align:top"><p>99.0</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>-1.0 (-2.1, -0.4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.74 (0.69, 0.79)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>23F</p></td><td style="vertical-align:top"><p>91.5</p></td><td style="vertical-align:top"><p>91.8</p></td><td style="vertical-align:top"><p>-0.3 (-3.2, 2.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.89 (0.80, 0.99)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td colspan="7"><p>2&nbsp;Additional Serotypes in Vaxneuvance</p></td></tr><tr><td><p>22F</p></td><td style="vertical-align:top"><p>98.6</p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>95.1 (93.1, 96.5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>4.91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>92.03 (83.47, 101.47)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>33F</p></td><td style="vertical-align:top"><p>87.3</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>85.2 (82.3, 87.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>29.50 (26.16, 33.26)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>* Estimated difference and CI for the percentage point difference are based on the Miettinen &amp; Nurminen method.</p><p>** GMC ratio and CI are calculated using the t-distribution with the variance estimate from a serotype-specific linear model utilising the natural log-transformed antibody concentrations as the response and a single term for vaccination group.</p><p><sup>&dagger;</sup> A conclusion of non-inferiority for the 13&nbsp;shared serotypes is based on the lower bound of the 95%&nbsp;CI being &gt; -10&nbsp;percentage points for the difference in IgG response rates (Vaxneuvance &ndash; 13-valent PCV) or &gt; 0.5 for the IgG GMC ratio (Vaxneuvance/13-valent PCV).n=Number of participants randomised, vaccinated and contributing to the analysis.</p><p>CI=confidence interval; GMC=geometric mean concentration (&micro;g/mL); IgG=immunoglobulin G.</p><p>&nbsp;</p><p>At 30&nbsp;days following the toddler dose, serotype‑specific IgG GMCs for Vaxneuvance are noninferior to the 13-valent PCV for all 13&nbsp;shared serotypes and for the 2&nbsp;additional serotypes as assessed by the IgG GMCs for serotypes&nbsp;22F and 33F in Vaxneuvance recipients compared with the IgG GMC for serotype&nbsp;4 in the 13-valent PCV recipients (the lowest IgG GMC for any of the shared serotypes, excluding serotype&nbsp;3) with a GMC ratio of 4.69 and 2.59, respectively (Table&nbsp;5).</p><p>&nbsp;</p><p>Vaxneuvance induces immune responses to shared serotype 3 and the 2 additional serotypes, which were substantially higher compared to the immune response induced by the 13-valent PCV, as assessed by IgG response rates and IgG GMCs at 30&nbsp;days following the toddler dose (Table&nbsp;5).</p><p>&nbsp;</p><p><strong>Table 5: Serotype-specific IgG response rates and IgG GMCs at 30 days following the toddler dose (4-dose regimen, Protocol&nbsp;029)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3"><p><strong>Pneumococcal Serotype</strong></p></td><td colspan="3"><p><strong>IgG response rates &ge;0.35&nbsp;&micro;g/mL</strong></p></td><td colspan="3"><p><strong>IgG GMCs</strong></p></td></tr><tr><td><p><strong>Vaxneuvance</strong></p><p><strong>(n=712-716)</strong></p></td><td><p><strong>13-valent PCV (n=677-686)</strong></p></td><td rowspan="2"><p><strong>Percentage Point Difference*</strong></p><p><strong>(Vaxneuvance - 13-valent PCV)</strong></p><p><strong>(95% CI)*</strong></p></td><td><p><strong>Vaxneuvance</strong></p><p><strong>(n=712-716)</strong></p></td><td><p><strong>13-valent PCV (n=677-686)</strong></p></td><td rowspan="2"><p><strong>GMC Ratio**</strong></p><p><strong>(Vaxneuvance/</strong></p><p><strong>13-valent PCV)</strong></p><p><strong>(95%&nbsp;CI)**</strong></p></td></tr><tr><td><p><strong>Observed Response</strong></p><p><strong>Percentage</strong></p></td><td><p><strong>Observed Response</strong></p><p><strong>Percentage</strong></p></td><td><p><strong>GMC</strong></p></td><td><p><strong>GMC</strong></p></td></tr><tr><td colspan="7"><p>13&nbsp;Shared Serotypes<sup>&dagger;</sup></p></td></tr><tr><td><p>1</p></td><td style="vertical-align:top"><p>96.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-2.8 (-4.4, -1.4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.66 (0.62, 0.72)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>3</p></td><td style="vertical-align:top"><p>94.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>86.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>7.1 (4.0, 10.2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.35 (1.25, 1.46)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>4</p></td><td style="vertical-align:top"><p>95.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>97.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-2.4 (-4.5, -0.4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>1.60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.77 (0.71, 0.84)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>5</p></td><td style="vertical-align:top"><p>99.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-0.7 (-1.7, 0.1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3.95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.63 (0.58, 0.69)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>6A</p></td><td style="vertical-align:top"><p>98.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-0.5 (-1.7, 0.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3.70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>6.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.60 (0.54, 0.65)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>6B</p></td><td style="vertical-align:top"><p>98.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-0.5 (-1.7, 0.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>4.76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>6.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.74 (0.67, 0.81)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>7F</p></td><td style="vertical-align:top"><p>99.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-0.3 (-1.1, 0.4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>4.85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.70 (0.65, 0.77)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>9V</p></td><td style="vertical-align:top"><p>99.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-0.3 (-1.2, 0.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.73 (0.67, 0.80)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>14</p></td><td style="vertical-align:top"><p>99.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-0.3 (-1.2, 0.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>5.61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>6.95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.81 (0.73, 0.89)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>18C</p></td><td style="vertical-align:top"><p>99.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.2 (-0.6, 1.0)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.85 (0.78, 0.93)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>19A</p></td><td style="vertical-align:top"><p>99.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.0 (-0.7, 0.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>5.53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.74 (0.68, 0.80)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>19F</p></td><td style="vertical-align:top"><p>99.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.0 (-0.8, 0.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>4.47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.79 (0.74, 0.86)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>23F</p></td><td style="vertical-align:top"><p>98.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>99.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-0.4 (-1.7, 0.9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>2.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.61 (0.56, 0.68)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td colspan="7"><p>2&nbsp;Additional Serotypes in Vaxneuvance</p></td></tr><tr><td><p>22F</p></td><td style="vertical-align:top"><p>99.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>92.4 (90.1, 94.2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>7.52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>68.80 (63.10, 75.02)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>33F</p></td><td style="vertical-align:top"><p>98.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>92.7 (90.4, 94.4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>4.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>0.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>44.91 (41.04, 49.14)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>* Estimated difference and CI for the percentage point difference are based on the Miettinen &amp; Nurminen method.</p><p>** GMC ratio and CI are calculated using the t-distribution with the variance estimate from a serotype-specific linear model utilising the natural log-transformed antibody concentrations as the response and a single term for vaccination group.</p><p><sup>&dagger;</sup> A conclusion of non-inferiority for the 13&nbsp;shared serotypes is based on the lower bound of the 95%&nbsp;CI being &gt; 0.5 for the IgG GMC ratio (Vaxneuvance/13-valent PCV).</p><p>n=Number of participants randomised, vaccinated and contributing to the analysis.</p><p>CI=confidence interval; GMC=geometric mean concentration (&micro;g/mL); IgG=immunoglobulin G.</p><p>&nbsp;</p><p>Vaxneuvance elicits functional antibodies, as assessed by serotype‑specific OPA GMTs at 30&nbsp;days following the primary series and following the toddler dose, that are generally comparable but slightly lower for the 13&nbsp;serotypes shared with 13-valent PCV. The clinical relevance of this slightly lower response is unknown. OPA GMTs for both 22F and 33F were higher in Vaxneuvance recipients compared to the 13-valent PCV recipients.</p><p><em>&nbsp;</em></p><p><em>Infants and children receiving a mixed dose regimen of different pneumococcal conjugate vaccines</em></p><p>In a double-blind, active comparator-controlled, descriptive study (Protocol 027), 900 participants were randomised in a 1:1:1:1:1 ratio to one of five vaccination groups to receive a complete or mixed dosing regimen of pneumococcal conjugate vaccines. In two vaccination groups, participants received a 4-dose regimen of either Vaxneuvance or the 13-valent PCV. In the three other vaccination groups, the vaccination series were initiated with the 13-valent PCV and changed to Vaxneuvance at Dose&nbsp;2, Dose&nbsp;3 or Dose&nbsp;4. Participants also received other paediatric vaccines concomitantly, including HBVaxPro (Hepatitis B Vaccine [Recombinant]) and RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent). Serotype-specific IgG GMCs at 30 days following the toddler dose were generally comparable for participants administered mixed regimens of Vaxneuvance and the 13-valent PCV and for participants administered a complete dosing regimen of the 13-valent PCV for the 13 shared serotypes, as assessed by IgG GMC ratios.</p><p>Higher antibodies to serotypes 22F and 33F were only observed when at least one dose of Vaxneuvance was administered during primary infant series and at the toddler age.</p><p>&nbsp;</p><p><em>Immunogenicity in preterm infants</em></p><p>The immune responses (serotype-specific IgG and OPA) in preterm infants receiving 4 doses of pneumococcal conjugate vaccine in 4 double-blind, active comparator-controlled studies (Protocol&nbsp;025, Protocol&nbsp;027, Protocol&nbsp;029 and Protocol&nbsp;031), were generally consistent with those observed in the overall healthy infant population in these studies (including preterm and term infants).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Infants, children and adolescents receiving a catch-up vaccination schedule </u></em></p><p>In a double-blind, active comparator-controlled, descriptive study (Protocol&nbsp;024), 606 children who were either pneumococcal vaccine-na&iuml;ve or not fully vaccinated or completed a dosing regimen with lower valency pneumococcal conjugate vaccines were randomised to receive 1 to 3&nbsp;doses of Vaxneuvance or the 13-valent PCV in three different age cohorts (7 through 11&nbsp;months, 12 through 23&nbsp;months and 24&nbsp;months to less than 18&nbsp;years of age), according to an age-appropriate schedule. Catch-up vaccination with Vaxneuvance elicited immune responses in children 7&nbsp;months to less than 18&nbsp;years of age that are comparable to the 13-valent PCV for the shared serotypes and higher than the 13-valent PCV for the additional serotypes 22F and 33F. Within each age cohort, serotype-specific IgG GMCs at 30 days following the last dose of vaccine were generally comparable between the vaccination groups for the 13 shared serotypes and higher in Vaxneuvance for the 2 additional serotypes.</p><p>&nbsp;</p><p><em><u>Immune responses after subcutaneous administration</u></em><u> <em>in infants and children</em></u></p><p>In a double-blind, active comparator-controlled, descriptive study (Protocol&nbsp;033), 694 healthy Japanese infants from 2 to 6&nbsp;months of age were randomised to receive either Vaxneuvance or the 13-valent PCV as a 4-dose regimen via a subcutaneous route of administration. The first dose was given at 2 to 6&nbsp;months of age and second and third dose were given at an interval of &ge;27&nbsp;days from the prior dose. The fourth dose was administered at 12 to 15&nbsp;months of age. Vaxneuvance elicited serotype-specific immune responses (IgG and OPA) in healthy infants and toddlers that were generally comparable to the 13-valent PCV for the shared serotypes and higher in Vaxneuvance for the 2</p><p>additional serotypes.</p><p>&nbsp;</p><p><u>Clinical immunogenicity in immunocompetent adults &ge;18&nbsp;years of age</u></p><p>&nbsp;</p><p>Five clinical studies (Protocol&nbsp;007, Protocol&nbsp;016, Protocol&nbsp;017, Protocol&nbsp;019, and Protocol&nbsp;021) conducted in the Americas, Europe and Asia Pacific evaluated the immunogenicity of Vaxneuvance in healthy and immunocompetent adults across different age groups including individuals with or without previous pneumococcal vaccination. Each clinical study included adults with stable underlying medical conditions (e.g., diabetes mellitus, renal disorders, chronic heart disease, chronic liver disease, chronic lung disease including asthma) and/or behavioural risk factors (e.g., current tobacco use, increased alcohol consumption) that are known to increase the risk of pneumococcal disease.</p><p>&nbsp;</p><p>In each study, immunogenicity was assessed by serotype‑specific OPA and IgG responses at 30&nbsp;days postvaccination. Study endpoints included OPA geometric mean titres (GMTs) and IgG geometric mean concentrations (GMCs). The pivotal study (Protocol 019) aimed to show noninferiority of the OPA GMTs for 12 of 13 serotypes that Vaxneuvance shares with the 13‑valent pneumococcal polysaccharide conjugate vaccine, noninferiority and superiority for the shared serotype 3, and superiority for serotypes 22F and 33F, additional to Vaxneuvance. Superiority assessment of Vaxneuvance to the 13‑valent pneumococcal polysaccharide conjugate vaccine was based on the between‑group comparisons of OPA GMTs and the proportions of participants with a &ge;4‑fold rise in serotype‑specific OPA titres from prevaccination to 30&nbsp;days postvaccination.</p><p>&nbsp;</p><p><em><u>Pneumococcal vaccine‑na&iuml;ve </u></em><em><u>adults</u></em></p><p><em><u>&nbsp;</u></em></p><p>In the pivotal, double‑blind, active comparator‑controlled study (Protocol&nbsp;019), 1,205&nbsp;immunocompetent pneumococcal vaccine‑na&iuml;ve subjects &ge;50&nbsp;years of age were randomised to receive Vaxneuvance or the 13‑valent pneumococcal polysaccharide conjugate vaccine. The median age of participants was 66&nbsp;years (range: 50 to 92&nbsp;years), with approximately 69% over 65&nbsp;years of age, and approximately 12% over 75&nbsp;years of age. 57.3% were female and 87% reported history of at least one underlying medical condition.</p><p>&nbsp;</p><p>The study demonstrated that Vaxneuvance is noninferior to the 13‑valent pneumococcal polysaccharide conjugate vaccine for the 13&nbsp;shared serotypes and superior for the 2&nbsp;additional serotypes and for the shared serotype&nbsp;3. Table&nbsp;6 summarises the OPA GMTs at 30&nbsp;days postvaccination. IgG GMCs were generally consistent with the results observed for the OPA GMTs.</p><p>&nbsp;</p><p><strong>Table 6: Serotype‑specific OPA GMTs at 30&nbsp;days Postvaccination in Pneumococcal Vaccine‑Na&iuml;ve Adults &ge;50&nbsp;Years of age (Protocol&nbsp;019)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Pneumococcal</strong></p><p><strong>Serotype</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Vaxneuvance</strong></p><p><strong>(N = 602)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>13‑valent PCV</strong></p><p><strong>(N = 600)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>GMT Ratio*</strong></p><p><strong>(Vaxneuvance/13‑valent PCV)</strong></p><p><strong>(95% CI)*</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>GMT*</strong></p></td><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>GMT*</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>13&nbsp;Shared Serotypes<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>256.3</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>322.6</p></td><td style="vertical-align:top"><p>0.79 (0.66, 0.96)</p></td></tr><tr><td style="vertical-align:top"><p>3<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>216.2</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>135.1</p></td><td style="vertical-align:top"><p>1.60 (1.38, 1.85)</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>1125.6</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>1661.6</p></td><td style="vertical-align:top"><p>0.68 (0.57, 0.80)</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>447.3</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>563.5</p></td><td style="vertical-align:top"><p>0.79 (0.64, 0.98)</p></td></tr><tr><td style="vertical-align:top"><p>6A</p></td><td style="vertical-align:top"><p>596</p></td><td style="vertical-align:top"><p>5407.2</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>5424.5</p></td><td style="vertical-align:top"><p>1.00 (0.84, 1.19)</p></td></tr><tr><td style="vertical-align:top"><p>6B</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>4011.7</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>3258.2</p></td><td style="vertical-align:top"><p>1.23 (1.02, 1.48)</p></td></tr><tr><td style="vertical-align:top"><p>7F</p></td><td style="vertical-align:top"><p>597</p></td><td style="vertical-align:top"><p>4617.3</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>5880.6</p></td><td style="vertical-align:top"><p>0.79 (0.68, 0.90)</p></td></tr><tr><td style="vertical-align:top"><p>9V</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>1817.3</p></td><td style="vertical-align:top"><p>597</p></td><td style="vertical-align:top"><p>2232.9</p></td><td style="vertical-align:top"><p>0.81 (0.70, 0.94)</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>1999.3</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>2656.7</p></td><td style="vertical-align:top"><p>0.75 (0.64, 0.89)</p></td></tr><tr><td style="vertical-align:top"><p>18C</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>2757.7</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>2583.7</p></td><td style="vertical-align:top"><p>1.07 (0.91, 1.26)</p></td></tr><tr><td style="vertical-align:top"><p>19A</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>3194.3</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>3979.8</p></td><td style="vertical-align:top"><p>0.80 (0.70, 0.93)</p></td></tr><tr><td style="vertical-align:top"><p>19F</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>1695.1</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>1917.8</p></td><td style="vertical-align:top"><p>0.88 (0.76, 1.02)</p></td></tr><tr><td style="vertical-align:top"><p>23F</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>2045.4</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>1740.4</p></td><td style="vertical-align:top"><p>1.18 (0.96, 1.44)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>2&nbsp;Serotypes Additional to Vaxneuvance<sup>&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p>22F</p></td><td style="vertical-align:top"><p>594</p></td><td style="vertical-align:top"><p>2375.2</p></td><td style="vertical-align:top"><p>586</p></td><td style="vertical-align:top"><p>74.6</p></td><td style="vertical-align:top"><p>31.83 (25.35, 39.97)</p></td></tr><tr><td style="vertical-align:top"><p>33F</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>7994.7</p></td><td style="vertical-align:top"><p>597</p></td><td style="vertical-align:top"><p>1124.9</p></td><td style="vertical-align:top"><p>7.11 (6.07, 8.32)</p></td></tr></tbody></table><p>*GMTs, GMT ratio, and 95% CI are estimated from a cLDA model.</p><p><sup>&dagger;</sup>A conclusion of non-inferiority for the 13&nbsp;shared serotypes is based on the lower bound of the 95% CI for the estimated GMT ratio (Vaxneuvance/13‑valent PCV) being &gt;0.5.</p><p><sup>&Dagger;</sup>A conclusion of superiority for serotype&nbsp;3 is based on the lower bound of the 95% CI for the estimated GMT ratio (Vaxneuvance/13‑valent PCV) being &gt;1.2.</p><p><sup>&sect;</sup>A conclusion of superiority for the 2&nbsp;additional serotypes is based on the lower bound of the 95% CI for the estimated GMT ratio (Vaxneuvance/13‑valent PCV) being &gt;2.0.</p><p>N=Number of participants randomised and vaccinated; n=Number of participants contributing to the analysis.</p><p>CI=confidence interval; cLDA=constrained longitudinal data analysis; GMT=geometric mean titre (1/dil); OPA=opsonophagocytic activity; PCV=pneumococcal conjugate vaccine.</p><p>&nbsp;</p><p>In a double‑blind, descriptive study (Protocol&nbsp;017), 1,515&nbsp;immunocompetent subjects 18&nbsp;to 49&nbsp;years of age with or without risk factors for pneumococcal disease were randomised 3:1 and received Vaxneuvance or the 13‑valent pneumococcal polysaccharide conjugate vaccine, followed by PPV23 6&nbsp;months later. Risk factors for pneumococcal disease included the following: diabetes mellitus, chronic heart disease including heart failure, chronic liver disease with compensated cirrhosis, chronic lung disease including persistent asthma and chronic obstructive pulmonary disease (COPD), current tobacco use, and increased alcohol consumption. Overall, of those who received Vaxneuvance, 285&nbsp;(25.2%) had no risk factor, 620&nbsp;(54.7%) had 1&nbsp;risk factor, and 228&nbsp;(20.1%) had 2&nbsp;or more risk factors.</p><p>&nbsp;</p><p>Vaxneuvance elicited immune responses to all 15&nbsp;serotypes contained in the vaccine as assessed by OPA GMTs (Table&nbsp;7) and IgG GMCs. OPA GMTs and IgG GMCs were generally comparable between the two vaccination groups for the 13&nbsp;shared serotypes and higher in the Vaxneuvance group for the 2&nbsp;additional serotypes. Following vaccination with PPV23, OPA GMTs and IgG GMCs were generally comparable between the two vaccination groups for all 15&nbsp;serotypes.</p><p>&nbsp;</p><p>In a subgroup analysis based on the number of reported risk factors, Vaxneuvance elicited immune responses to all 15&nbsp;serotypes contained in the vaccine as assessed by OPA GMTs and IgG GMCs at 30&nbsp;days postvaccination in adults with no, 1, or 2 or more risk factors. The results in each subgroup were generally consistent with those observed in the overall study population. Sequential administration of Vaxneuvance followed 6&nbsp;months later by PPV23 was also immunogenic for all 15&nbsp;serotypes contained in Vaxneuvance.</p><p>&nbsp;</p><p><strong>Table 7: Serotype‑specific OPA GMTs at 30&nbsp;days Postvaccination in Pneumococcal Vaccine‑Na&iuml;ve Adults </strong><strong>18‑49&nbsp;Y</strong><strong>ears of Age With or Without Risk Factors for Pneumococcal Disease (Protocol&nbsp;017)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:625px"><tbody><tr><td style="vertical-align:top"><p><strong>Pneumococcal</strong></p><p><strong>Serotype</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Vaxneuvance</strong></p><p><strong>(N = 1,133)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>13‑valent PCV</strong></p><p><strong>(N = 379)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Observed GMT</strong></p></td><td style="vertical-align:top"><p><strong>95% CI*</strong></p></td><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Observed GMT</strong></p></td><td style="vertical-align:top"><p><strong>95% CI*</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>13 Shared Serotypes</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1019</p></td><td style="vertical-align:top"><p>268.6</p></td><td style="vertical-align:top"><p>(243.7, 296.0)</p></td><td style="vertical-align:top"><p>341</p></td><td style="vertical-align:top"><p>267.2</p></td><td style="vertical-align:top"><p>(220.4, 323.9)</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1004</p></td><td style="vertical-align:top"><p>199.3</p></td><td style="vertical-align:top"><p>(184.6, 215.2)</p></td><td style="vertical-align:top"><p>340</p></td><td style="vertical-align:top"><p>150.6</p></td><td style="vertical-align:top"><p>(130.6, 173.8)</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1016</p></td><td style="vertical-align:top"><p>1416.0</p></td><td style="vertical-align:top"><p>(1308.9, 1531.8)</p></td><td style="vertical-align:top"><p>342</p></td><td style="vertical-align:top"><p>2576.1</p></td><td style="vertical-align:top"><p>(2278.0, 2913.2)</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>1018</p></td><td style="vertical-align:top"><p>564.8</p></td><td style="vertical-align:top"><p>(512.7, 622.2)</p></td><td style="vertical-align:top"><p>343</p></td><td style="vertical-align:top"><p>731.1</p></td><td style="vertical-align:top"><p>(613.6, 871.0)</p></td></tr><tr><td style="vertical-align:top"><p>6A</p></td><td style="vertical-align:top"><p>1006</p></td><td style="vertical-align:top"><p>12928.8</p></td><td style="vertical-align:top"><p>(11923.4, 14019.0)</p></td><td style="vertical-align:top"><p>335</p></td><td style="vertical-align:top"><p>11282.4</p></td><td style="vertical-align:top"><p>(9718.8, 13097.5)</p></td></tr><tr><td style="vertical-align:top"><p>6B</p></td><td style="vertical-align:top"><p>1014</p></td><td style="vertical-align:top"><p>10336.9</p></td><td style="vertical-align:top"><p>(9649.4, 11073.4)</p></td><td style="vertical-align:top"><p>342</p></td><td style="vertical-align:top"><p>6995.7</p></td><td style="vertical-align:top"><p>(6024.7, 8123.2)</p></td></tr><tr><td style="vertical-align:top"><p>7F</p></td><td style="vertical-align:top"><p>1019</p></td><td style="vertical-align:top"><p>5756.4</p></td><td style="vertical-align:top"><p>(5410.4, 6124.6)</p></td><td style="vertical-align:top"><p>342</p></td><td style="vertical-align:top"><p>7588.9</p></td><td style="vertical-align:top"><p>(6775.3, 8500.2)</p></td></tr><tr><td style="vertical-align:top"><p>9V</p></td><td style="vertical-align:top"><p>1015</p></td><td style="vertical-align:top"><p>3355.1</p></td><td style="vertical-align:top"><p>(3135.4, 3590.1)</p></td><td style="vertical-align:top"><p>343</p></td><td style="vertical-align:top"><p>3983.7</p></td><td style="vertical-align:top"><p>(3557.8, 4460.7)</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1016</p></td><td style="vertical-align:top"><p>5228.9</p></td><td style="vertical-align:top"><p>(4847.6, 5640.2)</p></td><td style="vertical-align:top"><p>343</p></td><td style="vertical-align:top"><p>5889.8</p></td><td style="vertical-align:top"><p>(5218.2, 6647.8)</p></td></tr><tr><td style="vertical-align:top"><p>18C</p></td><td style="vertical-align:top"><p>1014</p></td><td style="vertical-align:top"><p>5709.0</p></td><td style="vertical-align:top"><p>(5331.1, 6113.6)</p></td><td style="vertical-align:top"><p>343</p></td><td style="vertical-align:top"><p>3063.2</p></td><td style="vertical-align:top"><p>(2699.8, 3475.5)</p></td></tr><tr><td style="vertical-align:top"><p>19A</p></td><td style="vertical-align:top"><p>1015</p></td><td style="vertical-align:top"><p>5369.9</p></td><td style="vertical-align:top"><p>(5017.7, 5746.8)</p></td><td style="vertical-align:top"><p>343</p></td><td style="vertical-align:top"><p>5888.0</p></td><td style="vertical-align:top"><p>(5228.2, 6631.0)</p></td></tr><tr><td style="vertical-align:top"><p>19F</p></td><td style="vertical-align:top"><p>1018</p></td><td style="vertical-align:top"><p>3266.3</p></td><td style="vertical-align:top"><p>(3064.4, 3481.4)</p></td><td style="vertical-align:top"><p>343</p></td><td style="vertical-align:top"><p>3272.7</p></td><td style="vertical-align:top"><p>(2948.2, 3632.9)</p></td></tr><tr><td style="vertical-align:top"><p>23F</p></td><td style="vertical-align:top"><p>1016</p></td><td style="vertical-align:top"><p>4853.5</p></td><td style="vertical-align:top"><p>(4469.8, 5270.2)</p></td><td style="vertical-align:top"><p>340</p></td><td style="vertical-align:top"><p>3887.3</p></td><td style="vertical-align:top"><p>(3335.8, 4530.0)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>2 Serotypes Additional to Vaxneuvance</p></td></tr><tr><td style="vertical-align:top"><p>22F</p></td><td style="vertical-align:top"><p>1005</p></td><td style="vertical-align:top"><p>3926.5</p></td><td style="vertical-align:top"><p>(3645.9, 4228.7)</p></td><td style="vertical-align:top"><p>320</p></td><td style="vertical-align:top"><p>291.6</p></td><td style="vertical-align:top"><p>(221.8, 383.6)</p></td></tr><tr><td style="vertical-align:top"><p>33F</p></td><td style="vertical-align:top"><p>1014</p></td><td style="vertical-align:top"><p>11627.8</p></td><td style="vertical-align:top"><p>(10824.6, 12490.7)</p></td><td style="vertical-align:top"><p>338</p></td><td style="vertical-align:top"><p>2180.6</p></td><td style="vertical-align:top"><p>(1828.7, 2600.2)</p></td></tr></tbody></table><p>*The within‑group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t‑distribution.</p><p>N=Number of participants randomised and vaccinated; n=Number of participants contributing to the analysis.</p><p>CI=confidence interval; GMT=geometric mean titre (1/dil); OPA=opsonophagocytic activity; PCV=pneumococcal conjugate vaccine.</p><p>&nbsp;</p><p><em><u>Sequential administration of pneumococcal vaccines in </u></em><em><u>adults</u></em></p><p><u>&nbsp;</u></p><p>The sequential administration of Vaxneuvance followed by PPV23 was assessed in Protocol&nbsp;016, Protocol&nbsp;017 (see section 5.1, <em><u>Pneumococcal vaccine‑na&iuml;ve adults</u></em>), and Protocol&nbsp;018 (see section 5.1, <em><u>Adults living with HIV</u></em>).</p><p>&nbsp;</p><p>In a double‑blind, active comparator‑controlled study (Protocol&nbsp;016), 652&nbsp;pneumococcal vaccine‑na&iuml;ve subjects &ge;50&nbsp;years of age were randomised to receive Vaxneuvance or the 13‑valent pneumococcal polysaccharide conjugate vaccine, followed by PPV23 one year later.</p><p>&nbsp;</p><p>Following vaccination with PPV23, OPA GMTs and IgG GMCs were comparable between the two vaccination groups for all 15&nbsp;serotypes in Vaxneuvance.</p><p>&nbsp;</p><p>Immune responses elicited by Vaxneuvance persisted up to 12&nbsp;months postvaccination as assessed by OPA GMTs and IgG GMCs. Serotype-specific OPA GMTs declined over time, as they were lower at Month&nbsp;12 than Day&nbsp;30, but remained above baseline levels for all the serotypes contained in either Vaxneuvance or the 13‑valent pneumococcal polysaccharide conjugate vaccine. OPA GMTs and IgG GMCs were generally comparable between the intervention groups at Month&nbsp;12 for the 13&nbsp;shared serotypes and higher for the 2&nbsp;additional serotypes among recipients of Vaxneuvance.</p><p>&nbsp;</p><p><em><u>Adults with prior pneumococcal vaccination</u></em></p><p>&nbsp;</p><p>In a double‑blind, descriptive study (Protocol&nbsp;007), 253&nbsp;subjects &ge;65&nbsp;years of age who were previously vaccinated with PPV23 at least one year prior to study entry were randomised to receive Vaxneuvance or the 13‑valent pneumococcal polysaccharide conjugate vaccine.</p><p>&nbsp;</p><p>IgG GMCs and OPA GMTs were generally comparable between the two vaccination groups for the 13&nbsp;shared serotypes and higher in the Vaxneuvance group for the 2&nbsp;additional serotypes.</p><p>&nbsp;</p><p>In a clinical study, in which another PCV was administered &le;1&nbsp;year after PPV23, reduced immune responses were observed for the common serotypes compared to immune responses observed when PCV was given either alone or before PPV23. The clinical significance of this is unknown.</p><p>&nbsp;</p><p><u>Clinical immunogenicity in special populations</u></p><p>&nbsp;</p><p><em><u>Children living with HIV</u></em></p><p>In a double-blind, descriptive study (Protocol 030), Vaxneuvance was evaluated in 203 children 6 to less than 18&nbsp;years of age living with HIV. Of these children, 17 (8.4%) had a CD4+ T-cell count &lt;500&nbsp;cells/&mu;L and plasma HIV RNA value &lt;50,000 copies/mL. In this study, 407 participants were randomised to receive a single dose of either Vaxneuvance or the 13-valent PCV, followed by PPV&nbsp;23 2&nbsp;months later. Vaxneuvance was immunogenic as assessed by serotype-specific IgG GMCs and OPA GMTs at 30 days postvaccination for all 15 serotypes contained in Vaxneuvance. Serotype-specific IgG GMCs and OPA GMTs were generally comparable for the 13 shared serotypes and higher for the 2 additional serotypes (22F and 33F). After sequential administration with PPV&nbsp;23, IgG GMCs and OPA GMTs were generally comparable at 30 days postvaccination between the two vaccination groups for all 15 serotypes contained in Vaxneuvance.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Adults living with HIV</u></em></p><p>In a double‑blind, descriptive study (Protocol&nbsp;018), 302&nbsp;pneumococcal vaccine‑na&iuml;ve subjects &ge;&nbsp;18&nbsp;years of age living with HIV with CD4+ T‑cell count &ge;50&nbsp;cells/&micro;L and plasma HIV ribonucleic acid (RNA) &lt;50,000&nbsp;copies/mL were randomised to receive Vaxneuvance or the 13‑valent pneumococcal polysaccharide conjugate vaccine, followed by PPV23 2&nbsp;months later. The majority of participants had a CD4+ T‑cell count &ge;200&nbsp;cells/&micro;L; 4 (1.3%) had a CD4+ T‑cell count &ge;50 to &lt;200&nbsp;cells/&micro;L, 152 (50.3%) had a CD4+ T‑cell count &ge;200 to &lt;500&nbsp;cells/&micro;L, and 146 (48.3%) had a CD4+ T‑cell count &ge;500 cells/&micro;L.</p><p>&nbsp;</p><p>Vaxneuvance elicited immune responses to all 15&nbsp;serotypes contained in the vaccine as assessed by OPA GMTs and IgG GMCs at 30&nbsp;days postvaccination. Immune responses seen in the HIV-infected participants were consistently lower compared to healthy participants but comparable for both vaccination groups, except for serotype 4. OPA GMT and IgG GMC for serotype 4 were lower for Vaxneuvance. After sequential administration with PPV23, OPA GMTs and IgG GMCs were generally comparable between the two vaccination groups for all 15&nbsp;serotypes.</p><p>&nbsp;</p><p><em><u>Children with Sickle Cell Disease</u></em></p><p>In a double-blind, descriptive study (Protocol 023), Vaxneuvance was evaluated in children 5 to less than 18&nbsp;years of age with sickle cell disease. In this study, participants enrolled may have received routine pneumococcal vaccines during the first two years of life but had not received pneumococcal vaccines in the 3 years prior to study entry. A total of 104 participants were randomised 2:1 to receive a single dose of either Vaxneuvance or the 13-valent PCV. Vaxneuvance was immunogenic as assessed by serotype-specific IgG GMCs and OPA GMTs at 30 days postvaccination for all 15&nbsp;serotypes contained in Vaxneuvance. Serotype-specific IgG GMCs and OPA GMTs were generally comparable between the two vaccination groups for the 13 shared serotypes and higher in Vaxneuvance for the two additional serotypes 22F and 33F.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Children and adults receiving Haematopoietic Stem Cell Transplant</u></em></p><p>In a double-blind, descriptive study (Protocol&nbsp;022), Vaxneuvance was evaluated in adults and children&nbsp;&ge;3&nbsp;years of age who had received an allogeneic haematopoietic stem cell transplant (allo‑HSCT) 3&nbsp;to 6&nbsp;months prior to enrollment. In this study, 277&nbsp;participants were randomised to receive 3&nbsp;doses of Vaxneuvance or the 13-valent PCV, administered one&nbsp;month apart. Twelve months after allo‑HSCT, participants without chronic graft-versus-host disease (cGvHD) received a single dose of PPV23 and those with cGvHD received a fourth dose of either Vaxneuvance or the 13-valent PCV. Vaxneuvance was immunogenic in recipients of allo‑HSCT, as assessed by IgG GMCs and OPA GMTs at 30&nbsp;days following the third dose of Vaxneuvance for all 15&nbsp;serotypes contained in the vaccine. Serotype-specific IgG GMCs and OPA GMTs were generally comparable between the two vaccination groups for the 13&nbsp;shared serotypes and higher in Vaxneuvance for the two additional serotypes (22F and 33F). Similarly, in participants who received either Vaxneuvance or the 13-valent PCV twelve months after allo‑HSCT, IgG GMCs and OPA GMTs at 30&nbsp;days following vaccination were generally comparable between the two vaccination groups for the 13&nbsp;shared serotypes and higher in Vaxneuvance for the two additional serotypes (22F and 33F). In participants who received PPV23 twelve months after allo-HSCT, IgG GMCs and OPA GMTs at 30 days following vaccination were generally comparable between the two vaccination groups for all 15 serotypes contained in Vaxneuvance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical study data revealed no hazard for humans based on conventional studies of repeated dose toxicity and toxicity to reproduction and development.</p><p>&nbsp;</p><p>Vaxneuvance administered to female rats had no effects on mating performance, fertility, embryonic/foetal development, or development of the offspring.</p><p>&nbsp;</p><p>Vaxneuvance administered to pregnant female rats resulted in detectable antibodies to all 15&nbsp;serotypes in offspring. This was attributable to the acquisition of maternal antibodies via placental transfer during gestation and possibly via lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride (NaCl)</p><p>L‑histidine</p><p>Polysorbate&nbsp;20</p><p>Water for injections</p><p>&nbsp;</p><p>For adjuvant, see section&nbsp;2.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C).</p><p>Do not freeze.</p><p>Keep the pre‑filled syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Vaxneuvance should be administered as soon as possible after being removed from the refrigerator.</p><p>&nbsp;</p><p>In the event of temporary temperature excursions, stability data indicate that Vaxneuvance is stable at temperatures up to 25&nbsp;&deg;C for 48&nbsp;hours.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.5&nbsp;mL suspension in pre‑filled syringe (Type&nbsp;I glass) with a plunger stopper (latex‑free bromobutyl rubber) and a tip cap (latex‑free styrene‑butadiene or latex-free isoprene-bromobutyl rubber).</p><p>&nbsp;</p><p>Pack sizes of 1 or 10&nbsp;pre-filled syringes, either without needles, with 1 separate needle, or with 2&nbsp;separate needles.</p><p>Multipacks containing 50 (5 packs of 10) pre-filled syringes without needles.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The vaccine should be used as supplied.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immediately prior to use, hold the pre-filled syringe horizontally and shake vigorously to obtain an opalescent suspension. Do not use the vaccine if it cannot be resuspended.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inspect the suspension visually for particulate matter and discolouration prior to administration. Discard the vaccine if particulates are present and/or if it appears discoloured.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attach a needle with Luer lock connection by twisting in a clockwise direction until the needle fits securely on the syringe.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject immediately using the intramuscular (IM) route, preferably in the anterolateral aspect of the thigh in infants or in the deltoid area of the upper arm in children and adults.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exercise care to avoid harm from an accidental needle stick.</p><p><strong>&nbsp;</strong></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder & Packaging Site:
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem 
The Netherlands

Manufacturer:
MSD International GmbH T/A MSD Ireland (Carlow)
Dublin Road,
Carlow, Co. Carlow,
Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sep 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>